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ABSTRACT
FUNCTIONAL PHOSPHORYLCHOLINE POLYMERS:
PRODRUGS AND BIOMATERIALS
MAY 2014
SAMANTHA B.M. PAGE, B.A., MOUNT HOLYOKE COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Todd Emrick

This thesis describes the synthesis and applications of multifunctional,
hydrophilic polymers consisting of a methacrylate backbone and zwitterionic
phosphorylcholine (PC) pendent groups, prepared by free radical polymerization of the
zwitterionic monomer, 2-methacryloyloxyethyl phosphorylcholine (MPC). Advances in
polymer chemistry, applied to PC polymers, allowed for the preparation of well-defined
structures with controlled molecular weight, narrow polydispersity, and facile
incorporation of functional comonomers, giving breadth to the range of materials
accessible for different applications. Built-in functionality included fluorophores and
reactive groups for post-polymerization transformations, such as drug conjugation or
cross-linking.

The ability to form well-defined structures based on the polyMPC

backbone is attractive to the fields of polymer therapeutics and biomaterials, due to the
high level of biocompatibility associated with PC polymers. The work presented here
examines methacrylate-based PC polymers as (1) polymer-protein conjugates, (2)
polymer prodrugs, and (3) polymeric hydrogels.

vi

In Chapter 2, synthetic advances center on tailoring chain-end functionality and
utilizing such structures as polymer-protein conjugates.

The design of new ATRP

initiators containing specific functionality allowed for polymer conjugation to lysozyme
as a model protein.

PolyMPC-lysozyme conjugates retained their native enzymatic

activity, and pharmacokinetic profiles of the conjugates in mice revealed increased
circulation half-life compared to lysozyme alone.
Chapter 3 describes PC-polymers that enhance intravenous drug delivery of
potent chemotherapeutic agents. Functionalized methacrylates for copolymerization with
MPC were designed, such that multiple copies of a drug can be loaded onto the polymer
backbone, affording highly water soluble polymer prodrugs with unprecedented drug
loading (>30 wt %). PolyMPC prodrugs of camptothecin (CPT) and doxorubicin (DOX)
demonstrated cytotoxicity against several human cancer cell lines in vitro. PolyMPCDOX prodrugs displayed prolonged circulation half-lives, and reduced uptake in healthy
tissue, enhanced accumulation in tumors, and superior treatment efficacy in 4T1-tumor
bearing mice.
Chapter 4 highlights multifunctional polyMPC as a precursor to new
phosphorylcholine hydrogels. Two cell lines, live mouse skeletal muscle myoblasts
(C2C12) and human ovarian cancer (SKOV3) cells, were observed to specifically attach,
spread, and proliferate on PC-hydrogels containing the GRGDS peptide sequence, with a
notable dependence on peptide concentration. The remarkable hydrophilicity and
biocompatibility attributed to polyMPC combined with facile gelation conditions affords
a platform of new bio-cooperative materials suitable for cell studies.
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CHAPTER 1
HYDROPHILIC POLYMERS FOR BIOMEDICAL APPLICATIONS
1.1 Introduction
Polymers have transformed society in many areas of science and technology,
including breakthroughs in biomedical applications.

Synthetic polymers now offer

unique and versatile platforms for drug delivery, as they can be chemically “bio-tailored”
for use as implants, medical devices, and injectable polymer-drug conjugates.1,2 While
several currently-used therapeutic proteins and small molecule drugs have benefited from
synthetic polymers, the full potential of polymer-based drug delivery platforms has not
yet been realized.

For injectable therapeutics, fundamental problems that can be

addressed with synthetic polymer delivery platforms include poor drug solubility in
aqueous media, short in vivo circulation time, fast clearance, and undesirable (even lifethreatening) side-effects. The first notion of improving drug behavior in vivo with a
polymer-drug conjugate came in the 1950’s,3 with the concept gaining momentum in the
1970’s when Ringsdorf and coworkers presented a model for polymer-drug conjugates.
The model is composed of three major components: a water-soluble polymer scaffold, a
therapeutic moiety covalently bound to the polymer, and a degradable (either
hydrolytically or enzymatically) linkage between the drug and the polymer backbone.4
Advances in polymer chemistry provided alternatives to standard linear polymers,
and architectures began to evolve, as well as drug-incorporation strategies, including
covalent conjugation and encapsulation techniques, and novel release mechanisms.5
Commonly used polymer architectures for biomedical and therapeutic systems are shown
in Figure 1.1. Typical linear polymers (Figure 1.1A) tend to suffer from limited drug
1

loading, where conjugation is generally restricted to chain-ends. Alterations to the
hydrophilic/lipophilic balance through, for example, block copolymers, lead to novel
self-assembled structures such as micelles and polymersomes, amenable to drug
encapsulation (Figure 1.1B and Figure 1.1C). In addition to drug delivery applications,
synthetic polymers also find use in other biomedical applications, including coatings for
medical implant devices6 (Figure 1.1D and Figure 1.1E) and water-swollen hydrogel
networks for regenerative medicine (Figure 1.1F).7-10 While these and other systems are
interesting for use in various applications, this thesis focuses on a new synthetic polymer
platform technology and demonstrates the breadth of applications accessible by simply
manipulating the chemistry.
(A)

(B)

(C)

(D)

(E)

(F)

Figure 1.1 Polymer architectures for biomedical applications: (A) linear polymers, (B)
micellar assemblies, (C) polymersomes, (D) thin film coatings, (E) surface-grafted
coatings, (F) cross-linked networks (hydrogel).
1.2 PEGylated polymers for medicine
Improving the efficacy and efficiency of therapeutics by focusing on the mode of
delivery, rather than the drug itself, is an emerging yet challenging area of interest in

2

medicine, where improved delivery vehicles present an opportunity to maximize the
therapeutic benefit of existing drugs. Synthetic polymers have long been established as
plastics, adhesives, foams, and rubbers, and more recently have emerged as key
components of drug delivery platforms.1,2 The notion of polymers for medicine has
expanded significantly in recent years, yet the potential for synthetic polymers in drug
delivery was identified early on.
poly(vinyl

In 1955, polymer-drug conjugates composed of

pyrrolidinone)-co-poly(acrylic

acid)

random

copolymers

containing

oligopeptide pendent groups were reported to prolong the circulation half-life relative to
the drug alone,3 suggesting the potential impact of synthetic polymers on drug delivery.
Poly(ethylene glycol) (PEG) has proven a “workhorse” polymer for medicine,
useful for both protein therapeutics as well as small molecule drugs. Conjugation of PEG
to therapeutics imparts the critically important characteristics of increased water
solubility and in vivo residence, and decreased enzymatic degradation and
immunogenicity.11

PEGylated therapeutic agents also are capable of passive tumor

targeting by the enhanced permeability and retention (EPR) effect.12-15 The EPR effect
refers to the preferential uptake of larger moieties (i.e., polymer conjugates) into the
“leaky” vasculature of cancer tissue relative to healthy tissue, and subsequent retention
due to poor lymphatic drainage.
Most commonly, PEGylation of therapeutic moieties is performed by coupling a
reactive chain end of PEG to a functional handle on the drug or protein, and the number
of reactive PEG derivatives available has undoubtedly contributed to its wide-spread use
in this field. Some of the more widely used chemistries for PEG attachment include
PEG-NHS ester or PEG-aldehyde for coupling to amines, and PEG-maleimide for thiol

3

coupling.5 Recent efforts geared towards expanding the scope of conjugation chemistry
include "click" chemistry; "click" reactions generally give high yields, produce byproducts which are easily removed, require mild conditions, and products are isolated by
facile methods.16
The PEGylated protein Adagen® was the first successful application of
PEGylation chemistry to a therapeutic protein, gaining FDA approval for the treatment of
severe combined immunodeficiency disease (SCID), and serving as an alternative to bone
marrow transplants.4,17 PEG Intron®, a PEGylated version of Intron A® (interferon--2b)
developed by Schering-Plough, is another example of a PEGylated protein exhibiting
advantages over the native protein in vivo. Interferon--2b is a cytokine that inhibits
tumor growth and angiogenesis, and is therapeutically relevant for treatment of hepatitis
B and C, malignant melanoma, and leukemia.18,19

To prepare PEG Intron®, a

succinimidyl carbonate functionalized PEG is conjugated to interferon--2b at histidine34, giving monoPEGylated protein.20 In vivo degradation of the carbamate releases the
protein during circulation in the bloodstream.

Other PEGylated proteins include

PEGylated erythropoietin (PEG-EPO) for the treatment of anemia resulting from
chemotherapy,21 and PEGylated granulocyte-colony stimulating factor (PEG-G-CSF),
used in chemotherapy treatment (marketed as Neulasta®), the success of which is
attributed to the greater solubilization provided by PEG, as well as the prevention of
aggregation.22
Synthetic polymers are also of current interest for enhancing delivery of smallmolecule cancer therapeutics. The use of polymers offers several advantages over the
drug alone, as well as small-molecule derivatives, for reasons relating to solubility,

4

reduction of toxic side effects, long circulation times due to slow renal clearance, and
passive tumor targeting by the EPR effect. Exploiting the EPR effect renders polymeric
materials a viable drug delivery platform, however actively targeted polymer-drug
conjugates are also desirable to increase the specificity of prodrug uptake to cancerous
tissues, while eliminating or reducing uptake (and potential damage) to healthy cells that
occurs despite the EPR effect.
One prominent example of a PEGylated small-molecule drug is camptothecin
(CPT), a topoisomerase I inhibitor, active against several types of cancer.23

CPT,

however, suffers from extremely poor water solubility, as well as physiological instability
of the E-ring lactone. Several synthetic derivatives have been synthesized to provide
better solubility, including the piperidinyl-functionalized Camptosar®. These derivatives
exhibit poor efficacy and life-threatening dehydration, among other side effects.5
Prothecan®, developed by Enzon, is one of the earliest examples of PEGylated CPT,
where two CPT molecules are covalently bound at the chain ends of a 40,000 g/mole
linear PEG through ester linkages at the 20-OH position of the drug.24 Modification at
this position inhibits lactone ring opening, a critically important factor in preserving the
therapeutic activity of the drug. Prothecan® displayed significantly improved circulation
time, with a half-life of more than 75 hours in patients with advanced solid
malignancies.25 Other examples of PEGylated CPT prodrugs include IT-101, a
PEGylated cyclodextrin containing polymer,26 PEG-SN38, a four-arm PEG star
containing four drugs per conjugate,27 as well as degradable PEGylated polyesters grafted
with pendent CPT molecules prepared by click chemistry.28
derivatives are shown in Figure 1.2.

5

These camptothecin

(A)

(B)

(C)

1

2

3
(E)

(D)

4
5

=
SN-38

Figure 1.2 (A) Camptothecin, (B) Camptosar® (irinotecan), (C) Prothecan®, (D) multiarm PEG star with four glycine-linked SN38 molecules, and (E) a PEGylated linear
cyclodextrin polymer bearing 2 glycine-linked CPT drugs per repeat unit.
Polymer micelles stemming from PEGylated block copolymer structures have
also proven useful in the delivery of hydrophobic drugs. Polymer micelles assemble
spontaneously following placement of amphiphilic polymers into selective solvents.
Hydrophobic-hydrophilic diblock copolymers in aqueous media are especially effective,
producing core-shell type structures in which the hydrophobic block collapses to generate
the core, leaving the hydrophilic block as the surrounding corona.

The core-shell

morphology of polymer micelles makes them ideally suited for drug delivery; the core
can function as an encapsulating matrix, while the shell, in addition to providing aqueous
solubility, presents unique opportunities for chemical functionality useful, for example,
for providing cellular recognition or targeting ligands. Polymer micelles bear some
resemblance to liposomal structures in that hydrophobic drugs can be sequestered into a
hydrophobic region and the structures are of appropriate size to exploit the EPR effect.
Polymer micelles represent a viable alternative to polymer-based drug delivery as the

6

polymer structure is chemically tunable, where, for example, stimuli responsive linkages
or cross-links can be incorporated and the size and shape can be controlled.
PEGylated block copolymer micelles have emerged as systems with great
potential in drug delivery, as they combine biocompatibility with synthetic versatility.
Relevant examples include poloxamers, also known by their trade name Pluronics®.
Pluronics® are composed of triblock copolymers of poly(ethylene oxide)-blockpoly(propylene oxide)-block-poly(ethylene oxide) (PEO-b-PPO-b-PEO) that form coreshell micelles in aqueous media, imparting the advantages of micellar platforms and also
contributing unique in vivo properties.29

Studies on doxorubicin (DOX)-loaded

SP1049C, a mixed micelle system of Pluronic® L61 and Pluronic® F127,30 indicated
activity against multiple DOX-sensitive cancer cell lines, with a 2-5 fold greater in vitro
sensitivity (IC50 values) relative to free DOX. Interestingly, these drug-loaded micelles
also showed orders-of-magnitude higher activity compared to free DOX against cancer
cell lines not normally sensitive to DOX. SP1049C is able to bind with DNA ten times
more efficiently than unmodified DOX, due to a combination of factors including an
increase in drug influx and tissue accumulation by the EPR effect, inhibition of efflux,
and changes in intracellular trafficking (i.e., is able to enter the cell by endocytosis rather
than relying solely on DOX diffusion).
Another DOX-encapsulated polymer micelle delivery system, reported in 2001 by
Kataoka and coworkers, used PEG-b-poly(aspartic acid) diblock copolymers, with DOX
attached covalently to the aspartic acid block.31 When taken up in water, the diblock
copolymer formed micelles, in which the DOX-conjugated hydrophobic block facilitates
additional physical sequestration of DOX into the hydrophobic core (the amide-linked
7

drug is stable under physiological conditions). These DOX-loaded micelles proved very
effective, resulting in cures against C-26 colon carcinomas (a model cancer cell line);
administration of free DOX did not result in any cures. Kataoka and coworkers added
sophistication to this polymer-DOX delivery system by attaching the drug to the
hydrophobic segment of the micelle through a hydrazine linkage,32 which releases the
drug in a pH dependent manner, by covalent bond cleavage at pH ~5. These polymer
micelles were constructed from PEG-block-poly(-benzyl-L-aspartate) (PEG-b-PBLA)
chains functionalized with hydrazide moieties, following removal of the benzyl
protecting groups from the aspartate repeat units. Conjugation of DOX with pendent
hydrazine moieties gives PEG-block-poly(ASP)37-co-poly(Asp-Hyd-DOX)28.

These

polymer-drug micelles were characterized by dynamic light scattering to be ~65 nm
average diameter, and displayed the desired pH dependent DOX release. Incubation of
these micelles with human small lung cancer SBC-3 cells revealed an effective inhibition
of cell growth, approaching that found in experiments using unmodified DOX.
Camptothecin may also benefit from delivery using PEGylated micelles. The
uptake and release of camptothecin was studied in vitro with poly(ethylene glycol)-bpoly(benzyl L-aspartate) (PEG-b-PBLA) micelles, in which the hydrophobicity of the
core was varied by controlling the percentage of benzyl ester protecting groups. 33
Micelles richer in benzyl ester groups (~two-thirds benzylated) were seen to more
effectively sequester the drug (~90 %). The same micelle also showed the slowest
camptothecin release (100 hours were needed to release ~80 % of the sequestered drug).
Synthetic polymers provide many varieties of opportunities for optimization of
drug delivery, including tools to alter solubility and biodistribution, reduce side effects,
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and increase the overall efficacy of the treatment. Chemical composition has clear
importance for biocompatibility and, in some cases, degradability, however polymer
architecture is also known to be of considerable importance. Novel synthetic polymers
will continue to benefit the medical community as new synthetic methodologies lead to
more efficient conjugation, encapsulation, and release chemistries.
1.3 Polyzwitterions
The growing interest in polymers for medicine has created a need for superior
polymer platform technologies that can be tailored to suit multiple chemical, physical,
and biological requirements.

While the benefits of PEGylation for increasing the

therapeutic efficacy of proteins and small molecule drugs have shown preliminary
success, other polymer structures present intriguing alternatives.

The phospholipid

bilayer of a cell membrane is considered optimal for interacting with biologics, thus
polymeric materials composed of synthetic phospholipid analogues have received much
effort and attention. These biomimetic analogues constitute a class of hydrophilic
polymers aside from the more conventional hydroxyl- and ether-rich structures (PEG),
known as polyzwitterions. Polyzwitterions are net-neutral, hydrophilic polymers, with
different architectures compared to conventional linear PEG prepared from ethylene
oxide ring-opening polymerization. The difference in backbone structure also renders
them amenable to different chemistries. Due to the presence of the zwitterion on each
repeat unit, polyzwitterions are well established as biocompatible and anti-fouling.34
Examples of these polymers are shown in Scheme 1.1, including poly(sulfobetaine
methacrylate) (polySBMA), poly(carboxybetaine methacrylate) (polyCBMA), and
poly(methacryloyloxyethyl phosphorylcholine) (polyMPC). This thesis will focus on
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new syntheses of functional phosphorylcholine methacrylates designed for applications in
prodrugs and biomaterials.
n

n

n

7

6

8

Scheme 1.1 Structure of polySBMA (6), polyCBMA (7), and polyMPC (8).
Phosphorylcholine

(PC)-based

polymers

resemble

naturally

occurring

phospholipids, and are hydrophilic due to the close association of water molecules with
the zwitterion (about 15-25 molecules per repeat unit).35 Perhaps most prominent among
PC-based polymers are those prepared from the methacrylic derivative
methacryloyloxyethyl phosphorylcholine (MPC).

2-

PolyMPC is quickly becoming

recognized as perhaps the most biocompatible synthetic polymer, lending itself to
applications in contact lenses, stents, and coatings for various medical devices and
implants.36-38
MPC monomer is polymerized using either conventional or controlled free radical
polymerization techniques.39 For the biomedical applications described in this thesis,
predictable molecular weights with narrow polydispersity indices were desirable,
requiring controlled "living" polymerization techniques, including atom transfer radical
polymerization (ATRP) and reversible addition-fragmentation transfer (RAFT)
polymerization.
ATRP is a versatile, copper-catalyzed radical polymerization technique which is
easily extended to MPC. This process relies on an equilibrium between an activated and
deactivated propagating species, mediated by a transition metal catalyst (usually copper
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(I) bromide or copper(I)chloride) which reversibly deactivates the propagating chain with
a terminal halogen.40 The ATRP mechanism is shown in Figure 1.3A. Typically a
halide-containing initiator is used, and the MPC polymerization is performed in
dimethylsulfoxide/methanol solvent mixtures to fully solubilize all components of the
reaction. The resulting MPC polymers are highly water-soluble (>100 mg/mL), with
close-to-targeted molecular weights and narrow polydispersity indices (PDI) (~1.1-1.3).
The polymers possess two well-defined end groups: one from the ATRP initiator, and the
halide that exchanges with the propagating chain.
RAFT polymerization is similar to ATRP in that it also is a form of living radical
polymerization. RAFT is based on the conventional free radical polymerization of an
alkene-bearing monomer, but is carried out in the presence of a chain transfer agent
(CTA).41 Common RAFT CTAs include dithioesters, dithiocarbamates, trithiocarbonates,
and xanthates, and are responsible for mediating the polymerization through a reversible
chain transfer process. The mechanism for RAFT is shown in Figure 1.3B. RAFT
represents an alternative approach to living polymerizations, where no metal catalyst is
required, as in the case of ATRP.
(A)

(B)

Figure 1.3 Mechanism of (A) ATRP and (B) RAFT polymerization.
11

Additional benefits of extending controlled polymerization techniques such as
ATRP and RAFT to MPC include the high degree of functional group tolerance. This
allows, for example, chain-end functionality to be easily installed on polyMPC by using
an initiator (ATRP) or CTA (RAFT) containing the desired functional group at the outset
of polymerization. End-functional polymers represent important precursor materials for
post-polymerization conjugation to proteins, ligands, fluorophores, or other therapeutic,
diagnostic, or targeting moieties. Furthermore, copolymers (random or block) can be
synthesized with ease by both ATRP and RAFT. This allows for functional monomers to
be incorporated, resulting in reactive sites along the polymer backbone for subsequent
drug conjugation, or for the addition of hydrophobic blocks to drive self-assembly into
nanoscale structures such as micelles or capsules.
1.4 Thesis Outline
The use of PC-polymers has largely been restricted to applications such as antifouling coatings due to the uncontrolled molecular weight and polydisperse nature of
polymers prepared by conventional free radical polymerization techniques. With the
advent of controlled polymerization techniques such as ATRP and RAFT, the synthesis
of well-defined PC-polymers with predictable molecular weights, end-group fidelity, and
functionality achieved through careful design of initiators or comonomers is now
possible. The purpose of this thesis was to investigate the synthesis of PC-methacrylates
and the incorporation of new functional groups. Reactive groups were installed at the
chain-end or as pendent groups along the backbone, giving novel random and diblock
copolymer structures.
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Chapter 2 describes the synthesis of MPC monomer and polymerization using
ATRP.

Polymers were synthesized in a range of molecular weights with narrow

dispersity and include specific chain-end functionality.

End-functional polyMPC is

explored for conjugation to proteins using lysozyme as a model (Biomacromolecules,
2008; Macromolecules, 2010; Biomacromolecules, 2012).42-44 Two conjugation strategies
were explored: 1) amine-reactive polyMPC was conjugated non-specifically to surface
available lysine residues and 2) ketone/aldehyde-reactive polyMPC was synthesized in
order to prepare polymer-protein conjugates with some degree of site-selectivity.
Chapter 3 describes PC-polymers that enhance the intravenous drug delivery of
the potent chemotherapeutic agents camptothecin (CPT)45,46 and doxorubicin (DOX)
(Bioconjugate

Chemistry,

2009;

Molecular

Pharmaceutics,

2013;

Molecular

Pharmaceutics, 2014).45-48 Functionalized methacrylates for copolymerization with MPC
were designed such that multiple copies of a drug can be loaded onto the polymer
backbone, affording highly water soluble polymer prodrugs with high drug loading (>30
wt %). PolyMPC prodrugs demonstrated cytotoxicity against several human cancer cell
lines in vitro.

PolyMPC-DOX prodrugs displayed prolonged circulation half lives,

preferential tumor accumulation, and superior treatment efficacy in 4T1 tumor-bearing
mice.
Lastly, Chapter 4 highlights multifunctional polyMPC as a precursor to new
phosphorylcholine hydrogels (Journal of Materials Chemistry B, 2014). The remarkable
hydrophilicity and biocompatibility of polyMPC combined with facile gelation
conditions affords a platform of new bio-cooperative materials suitable for cell studies.49
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CHAPTER 2
PHOSPHORYLCHOLINE METHACRYLATES FOR PROTEIN
CONJUGATION
2.1 Introduction
Covalent conjugation of synthetic polymers, such as poly(ethylene glycol) (PEG),
to therapeutic proteins is a clinically relevant example of polymer therapeutics.1-3 Such
PEGylated proteins exhibit improved therapeutic efficacy over the native proteins, with
prolonged in vivo circulation time resulting from enhanced protein stability in the
bloodstream, increased size, and an associated reduction in immunogenicity.4 A major
therapeutic benefit stemming from these characteristics is a decreased dosing frequency
required for effective therapy, enabled by the enhanced in vivo pharmacokinetics of the
PEGylated proteins.
Early pioneering studies of PEGylated proteins showed their therapeutic benefit,
using for example, PEGylated bovine serum albumin (BSA)5 and insulin.6 Numerous
proteins have since been PEGylated, including uricase,7 collagen,8 trypsin,9 alkaline
phosphatase,10 granulocyte colony stimulating factor (G-CSF),11 and interferon.12 The
commercial availability of PEG derivatives containing terminal functionality suitable for
protein conjugation, such as maleimides and N-hydroxysuccinimidyl (NHS)-esters,
contributed to the rapid advances in this field.
The aqueous solubility and protein resistant characteristics of PEG are attributed
to the association of water with the polyether backbone. The hydrophilic environment
extending from the polymer shields indiscriminant protein adsorption, as described for
PEGylated surfaces.13 Several other synthetic polymers have also been studied in protein
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conjugation, including poly(N-hydroxypropyl methacrylamide) (polyHPMA)14-17 and
poly(N-isopropylacrylamide) (polyNIPAAm).18-20
Methacryloyloxyethyl

phosphorylcholine

(MPC)

polymers,

despite

their

extensive track record of biocompatibility in coatings, contact lenses, and bloodcontacting devices such as stents, have been under-exploited for polymer therapeutics.21
Like PEG, polyMPC is hydrophilic due to an extensive association of water molecules
with the backbone (15-25 per repeat unit).21-22 Unlike PEG, which is an amphiphile,
polyMPC is strictly hydrophilic, exhibiting insolubility in nearly all organic solvents.
The absence of commercially available polyMPC derivatives has limited its use in protein
conjugation to only a few recent studies, including our published work presenting the first
report of end-functional polyMPC for protein conjugation.23-28 This thesis also discusses
subsequent efforts to expand the scope of conjugation chemistries available for use with
polyMPC.
2.2 NHS- and benzaldehyde-polyMPC for protein conjugation
Traditionally, non-specific conjugation to proteins is achieved by reaction of
surface available amine groups of lysine residues. Common functionalities employed to
achieve this type of conjugation include 1) activated esters, such as Nhydroxysuccinimidyl (NHS), forming stable amide bonds, and 2) aldehydes for reductive
amination chemistry where the initially-formed imine can be reduced irreversibly to an
amine linkage. Early efforts towards polyMPC for protein conjugation focused on these
two functional groups, incorporated at the polymer chain-end with an appropriately
functionalized ATRP initiator (Biomacromolecules, 2008).
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Until recently, MPC monomer was not readily commercially available, and was
prepared according to literature procedures.29 MPC was synthesized from reaction of 2hydroxyethyl methacrylate 9 (HEMA) and ethylene chlorophosphate, followed by ringopening with trimethylamine (Scheme 2.1).

Me3N
TEA, THF
9

10

11

n

8

Scheme 2.1 Synthesis of MPC (11) and polymerization to give polyMPC.
Compound 11 is isolated by filtration and lyophilization, giving the desired MPC
monomer as a white, hygroscopic powder in 50-60 % yield.

NMR spectroscopy

confirmed formation of the monomer, showing the characteristic methacrylate alkene
resonances (1H at 5.5 and 6.0 ppm), as well as the expected ring-opened phospholane
signal at 0 ppm in the
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P NMR spectrum. This process was found to be scalable,

ultimately producing ~60 grams per batch.
NHS- and benzaldehyde- functionalized initiators were prepared according to
Scheme

2.2

and

subsequently

used

to

polymerize

MPC

by

ATRP

in

methanol/dimethylsulfoxide solvent mixtures with Cu(I)Br and bipyridine as the catalyst
and ligand, respectively. These conditions give nearly quantitative monomer conversion
in 12 hours as judged by disappearance of monomeric olefins at 5.7 and 6.1 ppm, and the
appearance of broad signals centered at 1.0 and 2.0 ppm for the methyl and methylene
groups of the polymer backbone, respectively. The polymer products were purified by
21

elution through a short plug of silica gel to give white solids. Signals at 2.8 ppm arising
from the NHS methylenes, or at 9.7 ppm from the aldehyde resonance are useful for
molecular weight estimation by end-group analysis.

Polymers bearing the NHS or

aldehyde functionality demonstrated predictable molecular weights up to 10 kDa with
reasonably

narrow

polydispersities,

determined

by

aqueous

gel

permeation

chromatography (GPC) against linear poly(ethylene oxide) (PEO) standards (0.1 M
NaNO3 + 0.01 wt % NaN3). Molecular weights determined by GPC were in good
agreement with the results of end-group analysis from 1H NMR.

A summary of

polymerization results is provided in Table 2.1.

ATRP

n

TEA, THF

12

13

14

n
ATRP
TEA, THF

15

17

16

Scheme 2.2 Synthetic route to NHS- and benzaldehyde-functionalized polyMPC using
ATRP.
Table 2.1 Summary of polymerization results for polymers 14 and 17.
Sample

14 A
14 B
14 C
14 D
17 A
17 B
17 C

Initiator

13
13
13
13
16
16
16

Target
Molecular
Weight
(g/mole)

Conversion
by H NMR
Spectroscopy

3,200
4,500
7,500
11,000
4,000
6,000
8,000

Quantitative
Quantitative
Quantitative
Quantitative
Quantitative
Quantitative
Quantitative

1
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Molecular
Weight by
1

H NMR
(g/mole)
2,300
4,000
5,900
8,200
4,200
6,000
9,000

Aq. GPC
Mn
(g/mole)

Aq. GPC
PDI
(Mw/Mn)

3,500
5,200
7,700
9,600
4,500
7,000
9,700

1.5
1.2
1.5
1.3
1.1
1.1
1.1

NHS- and benzaldehyde-terminated polyMPC were tested for protein conjugation
using lysozyme as a model. Lysozyme is a 14.4 kDa protein isolated from chicken egg
white, and contains seven surface-available amine groups (6 from lysine residues, 1 from
the N-terminus of the protein) as possible reactive sites. PolyMPC samples 14 and 17
were conjugated to lysozyme under aqueous buffer conditions (from pH 6 to 9), and at
different functional group stoichiometry and concentration (Figure 2.1A).

The

conjugation reactions were monitored by high performance liquid chromatography
(HPLC) fitted with a size exclusion column, as well as by polyacrylamide gel
electrophoresis (SDS-PAGE).

Successful conjugation relied on working within an

appropriate concentration range; dilute conditions, using, for example, a 1 mg/mL protein
solution at pH 9.0 gave only ~25 % protein conjugation in 24 hours (conversion
estimated from the relative areas of protein and conjugate in the HPLC trace). However,
at ten-fold higher concentration, 80 % conversion was seen in 24 hours, with nearly
quantitative conversion achieved following a second addition of polymer. Clearly the
higher concentration is preferred, with the dual benefit of increasing the reaction rate and
reducing the impact of competitive hydrolysis of the NHS end-group. Further evidence
in support of lysozyme conjugation with polymer 14 was obtained by SDS-PAGE, which
separates the PC-protein conjugate (Figure 2.1C, lane 3) from unreacted lysozyme
(Figure 2.1C, lane 2). The conjugates smear on the gel (as seen also for PEGylated
proteins30,31) due to inherent polydispersity of the conjugates and variability in
conjugation sites. Lysozyme appears as a distinct band corresponding to ~15 kDa.
PolyMPC-lysozyme

conjugates

were

purified

by

fast

protein

liquid

chromatography (FPLC), using a Superose 6 10/300 preparative size exclusion column,
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eluting with PBS buffer at a flow rate 0.5 mL/min. As seen in Figure 2.1B, the proteinpolymer conjugate elutes over the range of 14-to-19 mL, a significantly lower retention
volume relative to lysozyme itself (20-21 mL), due to the larger size of the conjugate.
The bimodal nature of the conjugate peak is expected for samples in which there is
heterogeneity in the number of conjugated polymers per protein. Typically, the eluted
conjugate was collected in 1 mL fractions, with each analyzed further by HPLC with
size-exclusion columns.
Conjugate 18 (prepared from polyMPC 14) was used for preliminary in vivo
evaluation, specifically monitoring the pharmacokinetics.

Conjugate 18 and free

lysozyme were fluorescently tagged using an Alexa Fluor dye (AF647) and injected
subcutaneously in mice.

Blood was withdrawn at preselected time points and dye

concentration in the serum samples was analyzed using fluorescence spectroscopy. As
shown in Figure 2.1D, the conjugate displays the expected increased half life (t1/2) of 50
hours, compared to the t1/2 for the unmodified enzyme of 2.4 hours. These preliminary
findings confirmed that attachment of polyMPC to a protein would increase the
circulation half life, potentially increasing the overall therapeutic efficacy if this strategy
were used in conjunction with therapeutically-relevant proteins.
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Figure 2.1 Synthetic scheme for preparation of polyMPC-lysozyme conjugates (A) and
characterization including SEC-FPLC (B), SDS-PAGE (C) and preliminary
pharmacokinetic evaluation in mice (D).
While NHS-esters are well-established for protein conjugation to various
substrates, the susceptibility of NHS to hydrolysis in aqueous buffers can reduce the yield
of attempted conjugation.32 PolyMPC restricts solvent choices for the polymerization
and work-up to water, methanol, and mixtures of these with some other solvents, so loss
of the chain-end is likely (and has been characterized by NMR and UV/Vis
spectroscopy33) even before its use in the conjugation reaction. In an effort to preserve
the NHS polymer chain end on polyMPC, we also explored the use of ionic liquids as
polar, non-aqueous solvents for protein-polyMPC conjugation in high yield
(Macromolecules, 2010).27 Despite the success of this method, not all proteins will be
amenable to reactions in ionic liquids, thus more robust chain-end functionality would be
required to expand the scope of amine-reactive polyMPC structures in an aqueous
environment.
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2.3 Pentafluorophenyl ester-polyMPC
Pentafluorophenyl (PFP) esters, originally used in oligopeptide synthesis, react
selectively with amines, and are more hydrolytically stable than N-hydroxysuccinimidyl
(NHS) esters.34,35 PFP-containing polymers have been studied in different contexts; for
example, PFP-bearing chain transfer agents (CTAs) were synthesized for the
polymerization of methacrylates by reversible addition fragmentation chain-transfer
(RAFT), giving thermally responsive polymers having a PFP chain-end.36,37 RAFTpolymerized PFP-containing methacrylates produced reactive homopolymers35,38 and
copolymers39; end-functional polymers prepared by RAFT bearing the PFP group for
subsequent amidation were also reported.40

One example exploited a PFP-acrylate

copolymer as a surface coating, which allowed for subsequent protein immobilization.41
In addition, a PFP-norbornene monomer was polymerized by ROMP, giving
polynorbornene with demonstrated capacity for reaction with primary and secondary
amines.42 The work in this thesis represents the first example of PFP-functionalized
ATRP initiators for MPC polymerization, giving highly water soluble and biocompatible
polymers with chain-end functionality for fast and efficient protein conjugation
(Biomacromolecules, 2012).28 Additionally, various polymer architectures were explored
in conjunction with this chain-end functionality, including linear, two-arm, and graft-type
PC-polymers, derived from both methacrylate and cyclic olefin polymeric systems. In
PEGylated proteins, multi-arm versions of PEG provide an alternative architecture with
an envisaged “umbrella-like” coverage of the protein.43 The architecture of polymer
coverage may influence the properties of the conjugates, including activity,
immunogenicity, and in vivo pharmacokinetics.44
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Yamasaki, et al. reported that

attachment of two-arm PEG to proteins resulted in a higher retention of enzymatic
activity than linear PEG of similar molecular weight.45 Similarly, covalently connecting
a two-arm 10 kDa PEG to asparaginase reduced its antigenicity 10-fold relative to its
linear PEG counterpart.46,47

Taken together, these materials represent a novel PC-

polymer platform well-suited for protein conjugation and, ultimately, examination in
therapeutic settings.
Linear polyMPC was prepared from the novel ATRP initiator, PFP-ester 20,
shown in Scheme 2.3.

Compound 20 was prepared in 70 % yield by reacting

pentafluorophenol with 2-bromoisobutyryl bromide, isolated as a colorless liquid, and
characterized by 1H,

13

C, and

19

F NMR spectroscopy, and high resolution mass

spectrometry (HRMS) (calculated: 331.9483; found: 331.9434). PolyMPC 21 was then
prepared from initiator 20 by ATRP in a 1:1 DMSO/methanol solution in the presence of
Cu(I)Br/bipyridine

(bpy)

as

the

catalyst/ligand

system.

n

TEA, THF

19

Cu(I)Br, bpy
DMSO/MeOH

20

21

Scheme 2.3 Synthesis of linear PFP-containing ATRP initiator and polymerization of
MPC.
The PFP-terminated polyMPC structures synthesized ranged from 5,000 to 30,000
g/mole, with polydispersity index (PDI) values from 1.2 - 1.5, estimated by aqueous gel
permeation chromatography (GPC) (calibrated against linear PEO standards).

The

molecular weights were controlled by varying the monomer-to-initiator ratio, and
monomer conversion was monitored by 1H NMR spectroscopy (in CD3OD solution),
integrating monomer alkene resonances (5.4 and 6.0 ppm) against the polymer methyl
27

protons (1.0 ppm). At attempted higher molecular weight, some loss of control was
noted by slightly higher PDI values. Following polymerization, the Cu catalyst was
oxidized by exposure to air, and spent catalyst, ligand, and residual monomer were
removed by passage through a short plug of silica, eluting with methanol. The pure
polymer was isolated by precipitation into THF.
expected backbone structure, and

19

1

H NMR spectroscopy confirmed the

F NMR showed the presence of the intact PFP-ester

chain-end, with expected resonances at -152.9, -157.2, and -162.0 ppm in an integrated
ratio of 2:1:2. PolyMPC 21 retained the PFP-ester end group even after several days in a
solution of pH 9 sodium borate buffer with D2O, as judged by

19

F NMR spectroscopy,

showing no liberated pentafluorophenol, confirming PFP as a more robust end-group.
Characterization data for three representative polymer samples is provided in Table 2.2.
Table 2.2 Polymerization results for polyMPC 21: target molecular weight calculated
from monomer:initiator ratio; percent conversion determined by 1H NMR spectroscopy;
peak elution time, Mn, Mw, and PDI determined by aqueous GPC against linear PEO
calibration standards.
Polymer
21A
21B
21C

Target MW
(g/mole)
6,000
20,000
40,000

%
Conversion
Quantitative
90 %
85 %

Peak Elution
Time (min)
26.4
24.9
23.3

Mn
(g/mole)
5,000
11,700
27,000

Mw
(g/mole)
6,300
15,000
40,500

PDI
(Mw/Mn)
1.2
1.3
1.5

Two-arm PFP-polyMPC structures were synthesized and examined as alternatives
to linear polymer conjugation, noting that one example of two-arm polyMPC can be
found in a published patent for reductive amination.48

Two-arm polyMPC was

synthesized by incorporating a branching point into the ATRP initiator using bishydroxymethyl propionic acid (bis-MPA), as shown in Scheme 2.4. Acid chloride 23
was prepared from 22 with oxalyl chloride in CH2Cl2 followed by esterification with
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ethylene glycol to give 24 as a colorless oil. The ethylene glycol linker provides spatial
extension between the PFP group and the quaternary carbon of the branch point, an
aspect found to be critical for successful protein conjugation.28 Reaction of 24 with
bis(pentafluorophenyl) carbonate gave PFP-initiator 25, isolated as a pale yellow oil in 76
% yield. The structure of 25 was confirmed by 1H, 19F, and

13

C NMR spectroscopy, as

well as HRMS (calculated: 684.9730; found: 684.9697). MPC polymerization using
initiator 25 proceeded by ATRP in DMSO/methanol to give two-arm polyMPC 26 as a
white solid, which was purified by precipitation into anhydrous THF or acetone.
(COCl)2
DCM/DMF(cat)
reflux

THF, TEA

24
22

23
THF, TEA

MPC
Cu(I)Br, bpy
MeOH, DMSO
n

26

25

Scheme 2.4 Synthesis of two-arm branched PFP-containing ATRP initiator 25 and
polymerization of MPC.
Polymers were synthesized over a range of molecular weights (Table 2.3), and
characterized by

1

H and

19

F NMR spectroscopy, and aqueous gel permeation

chromatography. GPC showed monomodal peaks with relatively narrow PDI values
(~1.3), suggesting that initiation at each site occurred without steric interference from the
other. The molecular weights estimated by GPC were slightly lower than the molecular
weight determined by 1H NMR spectroscopy and the monomer:initiator ratio.
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Table 2.3 Summary of polymerization results for two-arm PFP-polyMPC 26.
Polymer
26A
26B
26C
26D

Target MW
(g/mole)
6,000
10,000
20,000
40,000

Conversion
Quantitative
Quantitative
Quantitative
90 %

Peak Elution
Time (min)
25.2
25.1
24.7
24.0

Mn
(g/mole)
6,450
6,600
13,700
16,000

Mw
(g/mole)
9,200
8,600
17,600
21,500

PDI
(Mw/Mn)
1.4
1.3
1.3
1.4

The steric freedom of PFP-carbonate terminated polyMPC 26 required more
careful handling to avoid premature hydrolysis or methanolysis compared to the linear
counterparts.

Nonetheless, the end-group proved stable and effective when using

minimal methanol, and avoiding a silica column for purification.

Polymer 26 was

isolated by simply precipitating into anhydrous THF, with retention of the PFP-carbonate
chain end confirmed by 19F NMR spectroscopy.
To expand the scope of PC polymers containing PFP groups for conjugation, a
new set of structures was prepared by ring opening metathesis polymerization (ROMP) in
collaboration with Katrina Kratz in the Emrick research group.

This methodology

exploits prior synthesis of PC-polyolefins,49 while incorporating novel PFP-cyclooctene
comonomers. PFP-containing cyclooctene 29 was synthesized from the acid chloride of
carboxylate 28, giving compound 29 as a yellow oil in 78 % yield. Copolymers from 27
and 29 were synthesized using the pyridine-substituted version of Grubbs’ ruthenium
benzylidene

metathesis

catalyst

((H2IMes)(Cl)2(pyr)2RuCHPh)

trifluoroethanol/CH2Cl2 mixtures, as shown in Scheme 2.5.

31

in

Two samples of copolymer

31 of different molecular weights, each containing ~5 mole % PFP-ester monomer along
the backbone, as determined by NMR spectroscopy were prepared. Molecular weight
control was achieved by adjusting the monomer-to-catalyst feed ratio. Distinct from the
PFP-ester terminated polyMPC described previously, these PC-polyolefin copolymers
30

have PFP groups situated randomly along the backbone, providing new, graft-type
architectures for protein conjugation to the PC-polymer platform.
Catalyst 31
TFE/DCM

+
27

n

m

29

30

1. SOCl2
THF

2.

31
28

Scheme 2.5 Synthesis of PFP-COE 29, and ROMP copolymerization with PC-COE 27 to
give polymer 30.
2.4 Protein conjugates from PFP-containing polymers
PFP-terminated polyMPC was tested for conjugation to lysozyme, as shown in
Figure 2.2A, in pH 9 sodium borate buffer at room temperature. A lysozyme solution in
buffer at 10 mg/mL was added to ~20 molar equivalents of PFP-polyMPC 21. The
reactions were monitored and characterized by high performance liquid chromatography
(HPLC) and fast protein liquid chromatography (FPLC) (Figure 2.2B-C) using UV
detection at 280 nm. High yielding conversion to conjugate (>80 %) was observed
within 12 hours.

Following FPLC purification, no unreacted lysozyme remains, as

observed by SEC-FPLC (Figure 2.2C) and gel electrophoresis (SDS-PAGE) (Figure
2.2D). SDS-PAGE was carried out using gradient 4-15 % Tris-HCl polyacrylamide precast gels with 25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS buffer at pH 8.3. The
conjugates appear as polydisperse peaks by SEC, and as broad, smeared bands in SDS31

PAGE, which is attributed to the multiple reaction sites on lysozyme, as well as the
polydispersity and hydrophilicity inherent to the polyzwitterionic structure.
Similarly, lysozyme conjugates were prepared from two-arm PFP-polyMPC 26
and poly(PC-COE)-co-(PFP-COE) 30. The corresponding conjugates (Figure 2.2E and
Figure 2.2F) were purified and isolated by FPLC, dialysis and lyophilization. Unique to
the PC-polyolefins is the possible formation of conjugates consisting of multiple
polymers per lysozyme, and/or multiple proteins conjugated to a single polymer chain.
Considering the Mn and Mw values of these polymer samples, a percentage of the chains
will have 2 or more PFP groups, giving the possibility of soluble network structures that
cannot arise with PFP-terminated polyMPC. However, the excess of polymer used in
these conjugation reactions precludes the formation of large network structures.

Figure 2.2 Preparation of linear polyMPC-lysozyme conjugate (A) and characterization:
(B) SEC-FPLC of reaction mixture, (C) SEC-FPLC of purified conjugate, and (D) SDSPAGE of purified conjugate. The corresponding two-arm (E) and grafted (F) conjugates
were prepared under similar conditions.
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Dynamic light scattering was performed on the linear, branched, and grafted
polymer – protein conjugates prepared from comparable molecular weight polymers
(approximately 15,000 g/mole) to examine their size in solution using the Malvern
Zetasizer Nano series instrument. Native lysozyme had a measured diameter of 4.2 ± 0.1
nm in PBS solution at pH 7.4, and all of the lysozyme-polymer conjugates exhibited a
distinct increase in size, with diameters of 10.7 ± 0.2

nm and 8.6 ± 0.1

nm for

conjugates 32 (linear) and 33 (two-arm polyMPC), respectively. The grafted conjugate
34 displayed a large increase over the native enzyme, with a diameter of 22.7 ± 0.2 nm,
attributed to the possibility of producing small multifunctional structures. However, in
no case were unusually large structures seen that would be indicative of heavily
aggregated or cross-linked material.
Polymer-protein conjugates typically exhibit activity and/or efficacy that differ
from the native enzymes, depending to some extent on the proximity of the polymer to
the active site. Even when conjugation is at some distance from the active site, the
presence of the polymer may reduce activity if it becomes difficult (sterically) for the
enzyme to interact with its environment. PEGylated G-CSF (Neulasta®), for example,
retains 41 % of its native enzymatic activity.11 Prior studies with lysozyme conjugated to
a 5 kDa PEG chain showed suppressed enzymatic activity (77 %) relative to the native
enzyme,50 while a study on polyMPC-BSA and lysozyme conjugates showed 75-90 % of
native enzymatic activity.26 This data suggests that polymer conjugation does not
markedly reduce enzyme activity, but that a modest reduction in activity may result from
polymer shielding effects (steric interference).
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The enzymatic activity of the polymer-lysozyme conjugates prepared in this study
was tested using fluorescein-labelled Micrococcus lysodeikticus as the substrate. All the
samples were prepared at lysozyme-equivalent concentrations, determined by UV/Vis
spectroscopy with a standard curve constructed from different lysozyme concentrations at
280 nm. The substrate was incubated with the conjugates at 37 °C for one hour, then the
fluorescence intensity of each was measured by excitation at 485 nm, detecting emission
at 535 nm. The averaged measured values for the conjugates were compared to that of
native lysozyme, and are reported as relative activities on the substrate (Figure 2.3). A
no-enzyme control (NEC) experiment shows negligible background fluorescence in the
absence of lysozyme. The linear and two-arm polyMPC conjugates were found to retain
>80 % of the native enzymatic activity, while the graft conjugates retained >65 %. Two
different molecular weight conjugates of each type were tested and compared to native
lysozyme, with the results suggesting a correlation between polymer molecular weight
and the activity retained. For the linear, two-arm, and grafted conjugates using a 4 - 6.5
kDa polymer, the relative enzymatic activity was very high (>98 %). At higher polymer
molecular weight, lower activity was observed, specifically noted for the linear (84 %)
and grafted (69 %) conjugates. As mentioned previously, this reduced activity may be
due to steric interference of the enzyme with the substrate in the presence of these large
polymer chains.

34
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Figure 2.3 Results of fluorescence activity assay of lysozyme and lysozyme-polymer
conjugates using fluorescein-labeled Micrococcus lysodeikticus (485 and 535 nm
excitation and emission wavelengths, respectively). Samples were analyzed in triplicate.
Error bars represent ± standard deviation.
To evaluate the polyMPC - protein conjugates in vivo, lysozyme, linear, and twoarm polyMPC-lysozyme conjugates were labeled with Alexa Fluor 647 (AF647)
fluorescent dye. Such fluorescent labeling enables an evaluation of pharmacokinetics by
HPLC. Analysis of aliquots of blood withdrawn at various time points, was used to
determine the concentration of the conjugate in circulation at a given time. AF-labeled
conjugates were purified by passage through a bio-gel P4 column eluting with pH 7.4
PBS, where two well-separated bands were seen, corresponding to the labeled product
and unconjugated dye. The purified conjugates were concentrated and stored in solution
at 4 °C.

The purity of the AF-labeled structure was judged by SEC-HPLC with

fluorescence detection, exciting at 650 nm and monitoring emission at 670 nm. AF647
concentration was determined by UV/Vis spectroscopy, and the solutions of labeled
lysozyme and polyMPC-lysozyme were concentrated to 30 µg/mL (AF dye-equivalent
35

concentration). The labeled samples exhibited good stability at 4 °C for months, and
were stable to freeze-thaw cycles as confirmed by HPLC analysis following such
treatment. This feature is important for providing convenient and lengthy storage of
polyMPC-protein conjugates. To analyze the pharmacokinetic properties of polyMPClysozyme conjugates 32 and 33 compared to lysozyme itself, AF647-labeled samples
were injected intravenously into C57bl/6 mice (6 per group) at a dose of 1.5 mg/kg (AF
dye equivalent doses). At designated time points, aliquots of blood were withdrawn from
the animals. Following centrifugation and dilution with PBS, the serum samples were
analyzed by SEC-HPLC with fluorescence detection, exciting at 650 nm and monitoring
emission at 670 nm. AF647 dye concentrations in the samples at each time point was
determined using a calibration curve and were plotted against post-injection time to
generate the pharmacokinetics profiles of Figure 2.4.
The pharmacokinetic experiment reveals that polyMPC-lysozyme conjugate 32
remains in circulation much longer than lysozyme alone.

The signal from labeled

lysozyme became indistinguishable from the baseline in less than 12 hours, while the
signal from the linear polyMPC conjugate extended to 5 days. The t 1/2 of 0.9 hours for
free lysozyme was extended to 18 hours for the linear polymer-protein conjugate.
Surprisingly, the two-arm polyMPC-lysozyme conjugate 33 showed a t1/2 of only 1 hour,
though low protein concentrations were detected for several days post-injection, giving in
an increased area-under-the-curve (AUC) relative to native lysozyme, a phenomenon that
is not well-understood. The presence of the linear polyMPC provides a t1/2 that is ~30
times longer than the protein alone, and an AUC value ~24 times greater. In a study
using interferon-α2a (a 20 kDa therapeutic protein), conjugation to a 20 kDa PEG36

equivalent molecular weight polyMPC (as determined by GPC againt PEO standards)
was found to extend the elimination half life to 30 times that of the native enzyme25, a
result which is in excellent agreement with the findings presented here.

Figure 2.4 (A) Preparation of AF647-labeled polyMPC-lysozyme, (B) structure of
AF647-NHS, and (C) PK plot comparing lysozyme, linear polyMPC-conjugate, and twoarm polyMPC-conjugate.
2.5 PolyMPC for site-selective protein conjugation
While the amidation methods discussed in the previous sections can be facile and
effective for protein conjugation, it often yields non-selective attachment of multiple
polymer chains, and a distribution of conjugate sizes within a given sample. Site-specific
conjugation methods can eliminate the heterogeneity often associated with polymerprotein conjugates, producing well-defined samples with polymer attachment occurring
only at particular locations. To this end, Lewis and coworkers previously reported the
synthesis of a bis-sulfone polyMPC derivative for conjugation through disulfide
bridges,25 and Ishihara and coworkers subsequently reported the synthesis of a pyridine
disulfide functionalized polyMPC for conjugation to thiol-containing proteins,26 with
both approaches yielding well-defined polymer-protein conjugates.

Despite these

advances, some drawbacks are noted, including the multistep synthetic pathways needed
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to obtain the desired chain-end functionality, and that these particular examples are
limited to thiol conjugation.
The reaction between an aminooxy functional group and a ketone or aldehyde to
form a stable oxime bond has been explored as a route to chemoselective protein
conjugation.51-53 Ketones or aldehydes can be installed selectively on proteins through
various methods, including solid phase protein synthesis,51,54,55 protein engineering,56 and
chemical modification of amino acid residues.52 Oxime formation to afford polymerprotein conjugates has been exploited in the case of poly(N-isopropylacrylamide)
(PNIPAAm),53

poly(2-hydroxyethylmethacrylate)

(PHEMA),53

and

poly(PEG

methacrylate),53 with the oxime linkage found to be stable under physiological
conditions.56
In this work, oxime conjugation chemistry has been extended to polyMPC for
site-selective modification of proteins. This was accomplished by first synthesizing the
aminooxy-containing ATRP initiator 39, shown in Figure 2.5, as a shorter version of a
known structure containing a tetraethylene glycol linker.52 This was prepared by reaction
of ethylene glycol with 2-bromoisobutyryl bromide, giving compound 38 in 60 % yield,
followed by carbodiimide coupling of 38 with commercially-available (bocaminooxy)acetic acid to give initiator 39 in 85 % yield.

The structure of 39 was

confirmed by 1H NMR spectroscopy, specifically noting the t-boc protons at 1.5 ppm,
and the methyl protons of the isobutyryl group at 1.9 ppm. Initiator 39 was mixed with
MPC in a methanol/dimethylsulfoxide solution of Cu(I)Br/bipyridine as the
catalyst/ligand system, giving boc-aminooxy terminated polyMPC 40.
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Figure 2.5 Synthesis of aminooxy-functionalized ATRP initiator 39 and polyMPC 40.
Inset is 1H NMR spectrum before (a) and after (b) deprotection of the chain-end, showing
disappearance of boc proton signal at 1.5 ppm.
Polymerizations were generally performed at room temperature for 18 hours, and
monitored by 1H NMR spectroscopy. Monomer conversion typically reached >95 %,
determined by comparing the monomeric vinyl proton signals at 5.5 and 6 ppm with the
methyl and methylene protons of the polymer backbone at 1 and 2 ppm, respectively.
Polymers of varying molecular weights were obtained by adjusting monomer-to-initiator
ratio at the outset of polymerization, and the samples displayed relatively narrow
polydispersity indices (PDIs) (Table 2.4).

Molecular weight and PDI values were

characterized by aqueous gel permeation chromatography (GPC) against linear
poly(ethylene oxide) standards in 0.1 M sodium nitrate and 0.02 weight percent sodium
azide buffer. Successful deprotection of boc-aminooxy polyMPC in trifluoroacetic acid
was confirmed by 1H NMR spectroscopy, noting the loss of the t-boc proton signal at 1.5
ppm.

GPC analysis before and after deprotection revealed no change in molecular

weight, confirming the polymer backbone is stable to these deprotection conditions. The
aminooxy-terminated polymers were purified by dialysis against pure water, followed by
lyophilization to give the desired material as a white solid.
39

Table 2.4 Summary of polymerization results for aminooxy-polyMPC 40.
Sample

[M]:[I]

40A
40B
40C
40D

10:1
17:1
34:1
66:1

Target Mn
(g/mole)
3,300
5,400
10,450
20,000

Conversion
> 95 %
> 95 %
> 95 %
> 95 %

Mn
(g/mole)
2,400
5,000
7,700
15,000

PDI
(Mw/Mn)
1.4
1.3
1.4
1.5

Conditions suitable for reaction of aminooxy-terminated polyMPC were
examined prior to protein conjugation, by reaction with 4-hydroxybenzaldehyde as a
simple substrate, and one that provides a UV signature following conjugation. For
example, polymer 40 was dissolved in pH 5.5 phosphate buffer/dimethylsulfoxide
solution with 1.2 equivalents of 4-hydroxybenzaldehyde, and stirred at room temperature
(Figure 2.6A). After several hours, an aliquot was removed and analyzed by aqueous
GPC equipped with a UV detector (280 nm), showing substantial UV absorbance (Figure
2.6B) that reflects successful conjugation to the chain-end to give polymer 41.
Furthermore, 1H NMR spectroscopy showed a singlet at 8.4 ppm corresponding to the
syn addition product of the benzaldoxime chain-end, as well as signals at 7.05 and 7.64
ppm for the aromatic protons. End-group analysis by this technique indicated ~60 %
conversion to the oxime-linked polymer 41, confirming the ready availability of the
aminooxy chain-end for reaction with ketones and aldehydes.
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Figure 2.6 (A) Conversion of aminooxy-polyMPC 40 to benzaldoxime-polyMPC 41 and
(B) aqueous GPC before and after conjugation (UV detection at 280 nm).
Aminooxy polyMPC 40 was tested for protein conjugation using lysozyme as a
model enzyme.

Lysozyme was first modified with pentafluorophenyl (PFP) ester-

levulinate, compound 43 (prepared using a modified literature procedure52), to impart
ketone functionality to the protein. Conjugation of lysozyme to 43 was performed in pH
9 sodium borate buffer, with 10 % DMSO, at room temperature. After 2 hours, analysis
of the reaction mixture by cation exchange fast protein liquid chromatography (CEFPLC) indicated complete conversion of native lysozyme. Lysozyme-levulinate 44 was
purified by dialysis (MWCO 1000) against pure water, and isolated as a white solid
following lyophilization. The presence of multiple amine groups on lysozyme allows for
conjugation of more than one ketone per protein, and the molar ratio of lysoyzme to
pentafluorophenyl ester-levulinate dictates the degree of modification.

Electrospray

ionization (ESI) mass spectrometry confirmed successful conjugation, with multiple
ketones per lysozyme incorporated.

We note that the techniques used here for

conjugation and characterization are fully applicable to the synthesis of therapeutically
relevant bioconjugates containing only one reactive site.
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Scheme 2.6 Synthesis of lysozyme-levulinate 44 and polyMPC-lysozyme conjugate 45.
Lysozyme-polyMPC conjugation was carried out using aminooxy-terminated
polyMPC 40 with the ketone-modified enzyme 44. This was done in phosphate buffer
with 1:20 molar ratio of enzyme to polymer; conversion to conjugate 45 was monitored
by size exclusion high performance liquid chromatography (SEC-HPLC).

The

conjugation was tested under several conditions: at pH 7.4 and 5.5, and with and without
100 mM aniline as catalyst. Oxime formation was found to occur at a reasonable rate in
acidic pH, with aniline catalysis proceeding through a transimination reaction under
acidic aqueous conditions.57 Aliquots were removed from the reaction mixture at t = 2.5,
6, and 24 hours. Additionally, a control experiment was performed in which unmodified
lysozyme was mixed with aminooxy polyMPC, which, as expected, led to no conjugation
and elution of only native enzyme at 13 minutes. A representative HPLC chromatogram
is shown in Figure 2.7, demonstrating efficient and selective conjugation of polyMPClysozyme, with conjugate eluting from 5 - 11 minutes, and unreacted lysozyme-levulinate
eluting at 13 minutes.
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By comparing the peak elution time of the conjugate to a calibration curve
constructed from protein standards, the total molecular weight of the conjugate is an
estimated 30,000 g/mole, corresponding to approximately 2 polymer chains per
lysozyme. This is in good agreement with the estimated degree of functionalization of
lysozyme-levulinate obtained by ESI-MS. Optimum conjugation conditions were found
to be pH 5.5 phosphate buffer, with the presence of 100 mM aniline affording modest
improvement in conjugation efficiency.
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Figure 2.7 SEC-HPLC characterization of conjugation reactions: (A) lysozyme control;
(B) conjugation in PBS pH 5.5 + 100 mM aniline. Conjugate elutes from 5-11 minutes
and free protein elutes at 13 minutes. (C) SDS-PAGE analysis: Lane 1: protein
standards; Lane 2: native lysozyme; Lane 3: lysozyme-levulinate; Lane 4: lysozyme
control reaction; Lane 5: conjugation reaction at 24 hours in pH 5.5 PBS + 100 mM
aniline. (D) Conversion vs. time for conjugation at different pH and catalytic aniline
concentrations.
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PolyMPC-lysozyme conjugation was also analyzed by gel electrophoresis (Figure
2.7), which confirmed the SEC-HPLC findings. SDS-PAGE was done on gradient 4-15
% Tris-HCl polyacrylamide pre-cast gels with 25 mM Tris, 192 mM glycine, and 0.1 %
(w/v) SDS buffer at pH 8.3. Lane 1 shows broad-range protein standards (top to bottom:
209.0, 124.0, 80.0, 48.1, 34.8, 28.9, 20.6, and 7.1 kDa), and lanes 2 and 3 show native
lysozyme and lysozyme-levulinate, respectively. Lane 4 confirms that conjugate is not
formed in the absence of ketone functionality on lysozyme, and lane 5 shows the
polyMPC-lysozyme conjugate as a broad band due to polydispersity and hydrophilicity
inherent to the polymer, as well as the size distribution of conjugates within the sample
resulting from the potential for multi-site attachment.
2.6 Conclusions and future outlook
In summary, a series of linear, two-arm, and grafted polymer – protein conjugates
were prepared, exploiting active esters as chain-ends and pendent groups for protein
conjugation to PC-polymers. PFP-esters represent an alternative active ester for efficient
protein conjugation, with better hydrolytic stability than conventional NHS esters. DLS
experiments showed that varying the architecture and molecular weight of the polymer
affects the solution size of the conjugate, which in turn affects the pharmacokinetic
properties of a therapeutic conjugate, altering the absorption/elimination half lives and
effective exposure time.
Additionally, the synthesis of novel aminooxy-terminated MPC polymers using
ATRP for a site-selective approach to forming well-defined protein conjugates was
explored. These polymers are amenable to conjugation only with proteins bearing ketone
functionality, as demonstrated using levulinate-modified lysozyme as a model system.
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Conjugation conditions were optimized, demonstrating that the reaction is most efficient
at low pH in conjunction with catalytic aniline.
The combination of synthetic ease, conjugation efficiency, retained enzymatic
activity, and prolonged circulation time makes these structures interesting and potentially
valuable for future polymer therapeutics.

The examples presented here focus on

lysozyme as a model system, however, going forward, these and other conjugation
strategies will be applied to therapeutic proteins.
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CHAPTER 3
POLYMPC PRODRUGS FOR CHEMOTHERAPEUTICS
3.1 Introduction to polymer prodrugs
Advances in polymer therapeutics provide new opportunities for improving
pharmaceutical administration and delivery methods, including advances in experimental
approaches to chemotherapy.1,2,3 Small molecule antitumor agents used clinically often
display poor pharmacokinetics, undesired toxicity and side-effects, and poor water
solubility, presenting major delivery challenges. Numerous chemotherapeutic drugs used
today have a relatively low therapeutic index, or therapeutic ratio, described as the lethal
dose divided by the therapeutic dose (LD50/ED50). In essence, therapeutic benefits tend
to be offset by detrimental side effects. Covalently conjugating a small molecule drug to
a water-soluble polymer scaffold affords prodrugs with massively improved aqueous
solubility, longer in vivo circulation time (t1/2), and reduced side effects.1
Macromolecular scaffolds afford increased hydrodynamic size compared to the drug
alone, resulting in slower renal clearance, and increased uptake in tumor tissue by the
enhanced permeability and retention (EPR) effect.4 The EPR effect exploits preferential
uptake of large molecules due to the porous vasculature of tumor tissue, and subsequent
retention as a result of poor lymphatic drainage relative to healthy tissue.
Effective polymer prodrugs employ water-soluble, biocompatible polymers that
introduce potent cancer drugs (which are often hydrophobic compounds) effectively into
the bloodstream. In prodrug form, the drug payload is rendered inactive, with release
from the polymer scaffold dictated by the type of linkage between the drug and polymer.
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Upon release, active drug is recovered, and the inert polymer carrier clears from the
body. A schematic representation of this process is shown in Figure 3.1.

Figure 3.1 Schematic representation of polymer prodrug release mechanism in vivo.
Examples of hydrophilic polymers suitable for cancer drug delivery include
poly(ethylene glycol) (PEG),5 poly-N-(2-hydroxypropyl)methacrylamide (HPMA),6-9 and
cyclodextrin-based polymers.10,11 Prominent among PEGylated cancer drug candidates is
camptothecin (CPT), for which PEGylated versions show modestly enhanced circulation
time and reduced side effects.12 PEGylated camptothecin, reported by Enzon, Inc. as
Prothecan®, consists of a 40,000 g/mol PEG chain with camptothecin at each chain-end,
connected by ester linkages at the C-20-OH position of the drug.12

Another

chemotherapeutic agent, doxorubicin (DOX), has also been improved by PEGylation,
including for example, with linear PEG conjugation,13 as well as through sophisticated
architectures such as “bow-tie” dendrimers.14 The resulting polymer therapeutics display
increased water solubility, decreased toxicity, and enhanced specificity due to the action
of the EPR effect.
PolyMPC has been used extensively in bulk materials and coatings for contact
lenses and blood-contacting devices that require a high level of biocompatibility and
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resistance to protein adsorption.15-21 As polyMPC has a decidedly lower commercial
availability than functional PEG-based derivatives, its use in conjugation chemistry
towards polymer prodrug therapeutics has been limited.

Living free radical

polymerization techniques, such as ATRP22-25 and RAFT,26,27 now enable the preparation
of well-defined polyMPC-drug conjugates with diverse architectures that cannot be
achieved by conventional PEGylation techniques. In particular, through covalent grafting
to polyMPC copolymers, a very high drug loading can be envisaged, whereas PEGylation
chemistry confines covalent drug attachment to the polymer chain-end(s).
The work described here extends polyMPC to the area of polymeric prodrugs,
where small-molecule chemotherapeutics are covalently bound to the polymer backbone,
and retain their therapeutic efficacy upon liberation from the polymer carrier.

The

chemotherapeutic agents CPT and DOX were investigated as potential drug candidates to
be improved through the polyMPC delivery platform.
3.2 PolyMPC-CPT prodrugs by click chemistry
20(S)-Camptothecin (CPT), a natural alkaloid, was first isolated from the Chinese
tree Camptotheca acuminata in the 1960s.28 CPT shows potent anticancer activity over a
broad range of cancer cells,29,30 but has poor water solubility and high toxicity that has
limited its clinical use. The efficacy of CPT and its more water soluble counterparts,
topotecan and irinotecan, is compromised by ring-opening of the lactone (“E-ring”) to the
corresponding carboxylate under physiological conditions.31,32 Binding of the carboxylate
to serum albumin contributes to drug toxicity. In order to better solubilize CPT, its
conjugation to water soluble polymers has been explored, specifically by acylation at the
20-OH position; this carries an added benefit of stabilizing the ring-closed form of the
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drug.33 Water-soluble polymers such as poly(ethylene glycol) (PEG),12,34 poly-N-(2hydroxypropyl)methacrylamide

(HPMA),35,36

poly-L-glutamic

acid

(PG),37-39

cyclodextrin-based polymers,40,41 and PEG-grafted polyesters from the Emrick group42
have been used to conjugate CPT; these polymer-CPT conjugates show increased
efficacy over CPT to varying degrees.
The aim of this work was to apply click chemistry for CPT conjugation to the
polyMPC backbone, using an acylated and azide-modified CPT, to give polyMPC-CPT
conjugates with high drug loading and potential for future integration into CPT-based
injectable cancer therapeutics (Bioconjugate Chemistry, 2009). This project was done in
collaboration with Dr. Xiangji Chen, a post-doctoral researcher in the Emrick research
group.

Considering prior work that demonstrated the amenability of CPT to click

chemistry,42 polyMPC-g-CPT conjugates were prepared by combining this technique
with ATRP. Copolymerization of MPC with trimethylsilyl (TMS)-protected propargyl
methacrylate (TMS-PgMA), prepared from 3-TMS-propargyl alcohol and methacryloyl
chloride43 was first explored, however, this method proved unsatisfactory, as the ethyl 2bromoisobutyrate-initiated ATRP copolymerization of MPC and TMS-PgMA gave
copolymers with high PDI (nearly 2), and often multimodal elution peaks by GPC.
Moreover, 1H NMR spectroscopy of these copolymers indicated a loss of the TMS
protecting groups, likely the result of copper (I) acetylide formation during
polymerization, as similar results have been observed in other polar organic solvents.44
This undesired side-reaction promotes interchain coupling or even light cross-linking,
and control experiments showed that the TMS protecting group was indeed lost
completely when TMS-PgMA was stirred in solution under typical ATRP conditions.
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Considering the role of copper (I) acetylide as an intermediate in Cu(I)-catalyzed
Huisgen azide-alkyne click cycloaddition, ATRP and click cycloaddition were attempted
simultaneously, by introduction of CPT-azide 48 at the outset of the polymerization, as
shown in Figure 3.2. Monomer conversion was monitored by 1H NMR spectroscopy, and
cycloaddition was followed by disappearance of the CPT-azide N=N=N stretching signal
at ~2100 cm-1 in the FTIR spectrum. PolyMPC-g-CPT conjugate 49 prepared in this
fashion was purified by precipitation into THF, followed by passage over a short plug of
silica gel in mixed solvents.

Figure 3.2 (A) Synthesis of polyMPC-g-CPT copolymers (49) by one pot ATRP and
click chemistry; (B) aqueous GPC trace of copolymer 49; (C) plot of light scattering
intensity with concentration of copolymer 49 (inset is polymer diameter distribution).
PolyMPC-g-CPT was characterized by aqueous GPC as shown in Figure 3.2B, as
well as 1H and 13C NMR spectroscopy. A homogeneous distribution of CPT functionality
throughout the polymer molecular weight distribution was confirmed by overlaying the
UV and RI traces obtained from GPC characterization. Aqueous solution sizes of these
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structures were also characterized using dynamic light scattering (DLS), with the
copolymers largely forming unimers, in which the hydrophilic polymers are expected to
cover a collapsed core of hydrophobic CPT groups (Figure 3.2C). The graft copolymers
did not show a critical micelle concentration (CMC) up to 20 mg/mL (the highest
concentration tested) and the average diameter of these structures was 6.8 nm.
PolyMPC-g-CPT copolymers with different linkers between CPT and the polymer
backbone, as depicted in Figure 3.2A, were synthesized to investigate drug release
kinetics associated with ester linkages of variable neighboring hydrophilicity.

For

example, to contrast the case of the 6-azidohexanoic acid linker,42 2-[2-(2azidoethoxy)ethoxy]acetic acid was synthesized. This was done by oxidation of 2-[2-(2chloroethoxy)ethoxy]ethanol to the corresponding carboxylic acid using Jones reagent at
room temperature, followed by displacement of the chloride by reaction with NaN3 at 80
°C. The presence of the azide group was confirmed by its characteristic infrared spectral
signal at ~2100 cm-1, and -azido methylene resonance at 50.6 ppm in the

13

C NMR

spectrum. CPT-azide compounds were obtained by acylation of CPT with linkers using
carbodiimide coupling. Varying linker chemistry was found to have little-to-no effect on
the polymerization and cycloaddition reactions, as indicated by the relatively low PDI
values, and experimental agreement with theoretical drug loadings. Thus, this one-pot
click/ATRP procedure provides a facile one-step process to introduce CPT into
hydrophilic, biocompatible MPC polymer backbone with good control over drug loading.
The CPT loading on the polyMPC backbone could be varied easily by adjusting
the MPC:TMS-PgMA/CPT ratio at the outset of the polymerization, with exemplary
samples listed in Table 3.1. Importantly, PDI control was achieved at CPT loadings up to
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14 weight percent (compare this to SN-38-PEG 4-arm stars containing 3.7 wt % CPT45),
and the aqueous solubility of this highly drug-loaded polyMPC structure was excellent
(>250 mg/mL, or >35 mg/mL CPT equivalent). The lactone form of CPT alone has a
solubility of 2.5 μg/mL; thus use of the polyMPC framework provides orders-ofmagnitude greater solubility. Aqueous solutions of these conjugates exhibit viscosities
that qualitatively resemble pure water, a notable difference from PEGylated drugs that
often exhibit an undesirably high solution viscosity. The strongly hydrated zwitterionic
moiety affects a wide range of properties, from solubility to sliding friction,46 making
these structures more appealing for many biological applications, including injectable
therapeutics.
UV/Vis spectroscopy was found to be the most reliable method for determining
CPT loading. Recording the UV absorbance of the CPT-loaded polymer at 370 nm
allowed for the weight percent CPT in each polymer to be calculated, using known
concentrations of the CPT-azide compounds and their molar extinction coefficients. The
CPT loading for each sample is given in Table 3.1 as CPT weight percent. As expected,
the relative absorbance at 370 nm from CPT increased with increasing amount of CPT
incorporated, with experimental values corresponding closely to the theoretical CPT
incorporation.
Table 3.1 Summary of polyMPC-g-CPT copolymers prepared by one-pot procedure.
Sample
49A
49B
49C
49D
49E

Target
CPT (wt %)
5%
10 %
15 %
8.5 %
8.4 %

Conversion
94 %
96 %
Quantitative
Quantitative
Quantitative

Mn
(g/mole)
5,200
5,500
5,100
13,000
7,000
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PDI
1.27
1.25
1.36
1.31
1.26

Diameter
(nm)
5.3
5.5
5.7
9.3
6.8

CPT wt %
5.1 %
7.7 %
13.8 %
7.0 %
5.1 %

In vitro drug release studies were performed on polyMPC-g-CPT conjugates to
gauge their relative release rates and potential utility in delivery applications. CPTcarrying polyMPC materials were incubated in PBS at various buffered pH values (5.5,
7.4, and 9.1) to measure the CPT hydrolysis half-lives from the polymer backbone, with
the choice of backbone-to-drug linkage leading to significant changes in ester cleavage
and drug release. The hydrophobic 6-azidohexanoic acid linker was first chosen for CPT
conjugation, giving copolymers 49A-C (Table 3.1). These structures gave very little
hydrolysis over four days of incubation under several different aqueous conditions,
suggesting that this linker is too hydrophobic for potential future in vivo use.

To

expedite ester hydrolysis, the hydrophilic linker 2-[2-(2-azidoethoxy)ethoxy]acetic acid
was used to prepare copolymers 49D-E (Table 3.1). The results of hydrolysis studies of
these structures in different media are shown in Figure 3.3. SEC-HPLC was used to
monitor CPT release from 49D and 49E incubated in various media (PBS, mouse serum,
cell culture medium, and human plasma). The polymer-drug conjugate was observed to
elute at 9.4 minutes and free CPT eluted at 16.9 minutes. Over the course of 96 hours,
the conjugate peak was seen to decrease while the CPT peak increased, as expected, as
CPT is hydrolyzed from the polymer backbone. These copolymers, with half-lives of
210–220 hours in PBS (pH 7.4), showed much faster release profiles than polyMPC-gCPT copolymers prepared using 6-azidohexanoic acid linkers. These polymers also
showed significantly shorter half-lives in mouse serum (~80 hours), cell culture medium
(~40 hours) and human plasma (8-9 hours). The hydrophilicity and electron-withdrawing
effect of the alkoxy group α to the carboxylic acid aids in accelerating ester cleavage.
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Figure 3.3 Conjugate 49D and 49E degradation in different media at 37 °C.
HPLC characterization of CPT liberation from polyMPC-g-CPT conjugates
confirmed the importance of tailored linkers, and was informative for in vitro cell culture
evaluation of conjugate toxicity against various cell lines. Taking 49D and 49E as
examples, a much faster CPT release profile was seen in human plasma as compared to
CPT release rates in PBS. These CPT hydrolysis half-lives are, however, slower than
those reported for PEGylated-SN38 conjugates,45 leading to an expected longer blood
circulation time in vivo. The anti-cancer activity of these polyMPC-g-CPT structures
(49D and 49E) was tested against different cancer cell lines, including human breast
(MCF7), ovarian (OVCAR 3) and colon (COLO 205) adenocarcinoma cells by Dr.
Sangram Parelkar, a post-doctoral researcher in the Emrick research group. This was
done by incubating CPT-equivalent concentrations of 49D and 49E with these cells for
72 hours, followed by cell viability measurements using a luminescence plate reader.
Controls included a DMSO solution of CPT, and polyMPC itself. Dose response curves
showed that both 49D and 49E were potent against the cancer cell lines tested here and
importantly the noted cytotoxicity was through CPT only, since polyMPC by itself is
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non-toxic (Figure 3.4). The IC50 values show that both 49D and 49E induced cytotoxicity
at IC50 values higher than native CPT alone, resulting from the fact that CPT was slowly
liberated over time from the polymer chain. It can also be seen that the colon cancer cells
were most sensitive to polyMPC-g-CPT conjugates.
DMSO

OVCAR-3
OVCAR-3cells
cells

80
80
70
70
60
60
50
50
40
40
30
30
20
20

5

10

50

CPT (in DMSO)
polyMPC

100

Viability
% CellCell
Viabilities
Percentage

90
80
70
60
50
40
30
20

00

0.1
0.1 0.25
0.25 0.5
0.5

0.75
0.75

11

55

10
10

50
50

70

5

10

30
30
20
20

50

CPT (in DMSO)
polyMPC

100
DMSO

90
90
80
80
70
70
60
60
50
50
40
40
30
30
20
20
10
10

00

0.1
0.1 0.25
0.25 0.5
0.5

0.75
0.75

11

55

10
10

50
50

100
100

CPT
CPT
equivalent
equivalent
concentration
concentration
[M]
[M]
CPT
Concentration
[uM]
polyMPC-CPT
polyMPC-CPT
55(5
(5wt%
wt%CPT)
CPT)
CPT
CPT(in
(inDMSO)
DMSO)
polyMPC-graft-CPT
polyMPC-graft-CPT
P11
P11
polyMPC-CPT
polyMPC-CPT
44(7
(7wt%
wt%CPT)
CPT)
polyMPC
polyMPC
polyMPC-graft-CPT
polyMPC-graft-CPT
P10
P10

00

00

0.1
0.1 0.25
0.25 0.5
0.5

0.75
0.75

11

Cell type

49D

49E

CPT

50

MCF7

6.7

4.6

0.29

40
30

OVCAR-3

3.3

2.5

0.13

20

COLO 205

3.9

2.3

0.32

0

0.1

0.25

0.5

0.75

1

5

10

CPT equivalent
concentration
[M]
CPT
Concentration
[uM]

polyMPC-CPT
5 (5 wt% CPT)
polyMPC-graft-CPT
P11
polyMPC-CPT
4 (7 wt% CPT)
polyMPC-graft-CPT
P10

50

CPT (in DMSO)
polyMPC

polyMPC-CPT
polyMPC-CPT
55(5
(5wt%
wt%CPT)
CPT)
polyMPC-graft-CPT
polyMPC-graft-CPT
P11
P11
polyMPC-CPT
polyMPC-CPT
44(7
(7wt%
wt%CPT)
CPT)
polyMPC-graft-CPT
polyMPC-graft-CPT
P10
P10

100
DMSO

Figure 3.4 In vitro cytotoxicity of polyMPC-g-CPT conjugates in cell culture of human
breast (MCF7), ovarian (OVCAR 3) and colon (COLO 205) adenocarcinoma cells. Error
bars represent ± standard deviation.
3.3 Polymer micelles for drug delivery
In addition to conventional linear polymer-drug conjugates, alternative
architectures have been used with impressive results, including branched structures, such
as a dendritic PEG-polyester doxorubicin (DOX) conjugates,14,47 as well as numerous
reports of encapsulated drugs exploiting micellar and liposomal systems.48-50 Polymer
micelles are enabling materials in nanoscale therapeutics, generally prepared from
amphiphilic block copolymers where, in water, the hydrophobic block sequesters drug
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within the core, and the hydrophilic block serves as an encapsulating corona, imparting
both water solubility and stealth properties to the micelles.51-54 The ease with which
drug-loaded micelles can be prepared (usually by dialysis or dilution) makes these
nanostructures attractive for injectable therapeutics, however, their use can be
problematic as they tend to suffer from "burst release" kinetics, where a large percentage
of the payload is released very quickly.55 Dilution upon injection is also a concern: selfassembled polymer micelles are dynamic structures with an equilibrium between free and
associated polymer chains. Though polymeric micelles often have low critical micelle
concentrations (CMC), extreme dilution arising from intravenous injection shifts the
equilibrium toward free polymer, resulting in disassociation of the micelles and liberation
of the payload.55 An effective method to overcome these challenges is to stabilize
polymer micelles by covalent cross-linking.
Both shell and core cross-linked micelles have been prepared from a variety of
different chemistries, including cross-linking with bi-functional additives,56,57 free radical
polymerization,58,59 and photo-cross-linking.60,61 Reversing the cross-linking with an
environmental trigger is an area of great interest, and examples of pH cleavable and
redox sensitive cross-links have been reported.62-65 Cross-linking with disulfides may be
particularly important for drug delivery due to their triggered bond breakage under
physiologically-relevant

and

intracellular-specific

conditions;

the

intracellular

environment is up to 1000 times more reducing than extracellular fluids.66 Several recent
reports utilized disulfide cross-linked micelles as drug delivery vehicles. Thiols have
been introduced to polymers by post-polymerization modification, for example by thiol
functionalization of PEGylated poly(lysine) with N-succinimidyl 3-(2-pyridyldithio)-

61

propionate.67 Following micellization, oxidation led to core cross-linking, and treatment
with dithiothreitol (DTT) resulted in micelle dissociation. In another example, a random
copolymer of methacryloyloxyethyl phosphorylcholine (MPC), glycidyl methacrylate,
and stearyl methacrylate formed micelles ~100 nm in diameter, with disulfide crosslinking achieved by reaction of the epoxide with cystamine.68

The micelles were

responsive to DTT, and biocompatible. Disulfide cross-linked polymer micelles have
been reported as carriers for chemotherapeutic agents including doxorubicin (DOX)69,70
camptothecin (CPT),71 and paclitaxel (PTX).72,73 A recent example employed a block
copolymer of PEG and HPMA, where a percentage of the HPMA block was coupled to
lipoic acid. Micelles from this polymer were loaded with DOX, and cross-linked using
DTT.74 However, this post-polymerization modification lacked control over, and
characterization of, the degree of substitution. Moreover, the block copolymers were
water-insoluble.
The work described in this section presents the synthesis of novel block
copolymers based on polyMPC, where the second block is prepared from a lipoic acidbased methacrylate. This synthesis precludes the need for post-polymerization
modification to introduce thiols, and ensures the presence of a functional hydrophobic
block with known and easily tunable thiol content. These MPC-based block copolymers
proved water soluble, even with high percentages of the lipoic acid-containing block, and
self-assembled readily into nanoscale micelles. Such structures are presented as carriers
for CPT, in which a pyridyldithio-functionalized CPT71 was conjugated to the DHLA
block, thus sequestering CPT to the micelle core. The disulfide linkages allow for
controlled CPT release upon exposure to reducing conditions, as would be found upon
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cellular internalization. This environmental stimulus, coupled with the passive targeting
of the EPR effect inherent to polymer-based drug delivery systems, is of interest for
improving the outcome of polymer-based drug delivery (Molecular Pharmaceutics,
2013).
3.4 Synthesis of CPT-loaded polyMPC micelles
PolyMPC-DHLA block copolymers were synthesized by RAFT polymerization,
employing sequential monomer addition to form the block copolymers shown as 55 in
Figure 3.5. Monomer 51 was prepared in 80 % yield by carbodiimide coupling of 2hydroxyethyl methacrylate (9) and lipoic acid (50).75 The monomer was isolated as a
yellow oil, and stored as a CH2Cl2 solution at -80 °C to prevent disulfide exchange.
Stored in this way, monomer 51 was stable for months.
PolyMPC-DHLA diblock copolymers were prepared by first polymerizing MPC
using 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (52) and 4,4'-azobis(4cyanovaleric acid) (ACVA, 53) as the chain transfer agent and initiator, respectively, at
70 °C in methanol/dimethylsulfoxide solution.

Following conversion of MPC to

polymer, a DMSO solution of 51 was introduced under inert atmosphere, and the mixture
was stirred at 70 °C for 12 hours. The polymerization was terminated by immersing the
flask in liquid nitrogen, then allowing the mixture to warm while open to air. The
polymerizations were generally taken to >90 % conversion, as judged by 1H NMR
spectroscopy, comparing vinyl protons of the monomer (5.5 and 6.0 ppm) to methyl
protons on the polymer backbone (1.0 ppm). Polymer 54 was isolated as a pink solid
following purification by passage through a short plug of silica gel, and precipitation into
THF.
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Figure 3.5 (A) Synthesis of thiol-containing monomer 51 based on lipoic acid 50; (B)
Synthesis of MPC block copolymers; (C) 1H NMR spectroscopy of a representative
polymer sample; (D) Aqueous gel permeation chromatography of polymer 55.
Block copolymer 54 was reduced immediately to the free thiol form with NaBH4
(4 molar equivalents relative to lipoic acid). The reaction was complete in 2 hours, at
which point concentrated HCl was added to adjust the solution pH to ~3. The polymer
solution was dialyzed against methanol, then water, at 4 °C (MWCO 1,000).
Lyophilization gave polyMPC-DHLA (55) as a white solid.

Polymer 55 was

characterized by NMR spectroscopy, and GPC eluting with 0.1 M aqueous sodium nitrate
+ 0.02 % (wt) sodium azide or trifluoroethanol (TFE) (0.2 M sodium trifluoroacetate),
against linear PEO or PMMA calibration standards, respectively (Table 3.2). The extent
of DHLA incorporation was determined by 1H NMR spectroscopy in 1:1 CDCl3:MeOD,
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comparing the DHLA methylene signal at 2.5 ppm with the methyl protons of the
polymer backbone at 1.0 ppm. This showed the DHLA content to be well-controlled by
adjusting monomer feed ratios.

GPC in TFE revealed a well-defined (monomodal)

polymer signal, with PDI ~ 1.2. In water, a high molecular weight signal was also seen,
attributed to copolymer micellization in solution. Interestingly, aggregation of this sort
was not observed in our characterization of random copolymers of similar composition
and molecular weight. We hypothesize that this behavior arises from (1) the distinct
amphiphilicity of these diblock copolymers that leads to rapid solution assembly, and (2)
the dense concentration of thiols in the DHLA block that provides additional stability to
the micelles through disulfide formation.

We note that these diblock copolymers

maintained excellent water solubility (to the eye), even at the highest DHLA
incorporation of 41 mole percent (sample 55C).
Table 3.2 Summary of polymerization results for block copolymer 55.
Sample

Target Mol. Wt.
(g/mole)

Target % DHLA

55A
55B
55C

16,000
18,000
21,000

10 %
20 %
40 %

TFE GPC
Mn
PDI
24,800 1.19
26,900 1.24
22,300 1.15

% DHLA
15 %
23 %
41 %

The critical micelle concentration (CMC) of block copolymers 55A-C was
examined using a pyrene fluorescence probe. Briefly, serial dilutions of polymer were
prepared in PBS, and 5 μL of pyrene solution in acetone was added to each, giving a
pyrene concentration of 0.6 M. The samples were equilibrated at room temperature for
18 hours. Pyrene exhibits a shift in peak fluorescence intensity as it transitions from a
hydrophilic (334 nm) to hydrophobic environment (339 nm), and CMC is determined by
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plotting peak intensity against the log of the polymer concentration, as shown for
polymer 55C in Figure 3.6A. The onset of the sharp change in slope of the line is taken
as the CMC.

Dynamic light scattering (DLS) analysis of the same series of

samples/concentrations shows a non-linear relationship between the scattering intensity
and concentration, confirming the presence of nanoscale micelles above CMC (Figure
3.6B). CMC varied slightly among the polymer samples, with an observed dependence
on hydrophobic content; as expected, the CMC for polymer 55C was lowest due its
higher DHLA content (41 mole %). DLS measurements of block copolymers 55A-C
showed an increase in size with hydrophobic block length, with hydrodynamic diameters
of 15, 18 and 28 nm, respectively, measured at 1 mg/mL in PBS (Figure 3.6C).
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Figure 3.6 Summary of micelle characterization: (A) CMC determination using pyrene
fluorescence for block copolymer 55C; (B) scattering intensity vs. concentration from
dynamic light scattering for block copolymer 55C; (C) size (diameter) of micelles from
copolymers 55A-C.
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Thiol-containing micelles can self-cross-link by oxidation to disulfide form,
accomplished by continually purging the system with air. The process of disulfide
formation was monitored using Ellman's test,76 performed on polymer dissolved in PBS
above the CMC and agitated by bubbling a slow stream of air through the mixture. At
various time points, 10 uL aliquots were removed and added to a buffered solution of
Ellman's reagent, resulting in a decrease in intensity of the UV absorption at 412 nm as
the free thiol converted to disulfide (Figure 3.7A). This provides a spectroscopic handle
to monitor cross-linking efficiency. Samples generally reached 85 % conversion in 48
hours. Solutions simply left open to air, without bubbling, gave significantly lower
conversion (~20 % after two days).
Cross-linked micelles were characterized by DLS and TEM (Figure 3.7). DLS of
cross-linked micelles formed from polymer solutions at 1 mg/mL showed no difference
from the uncross-linked samples, suggesting that the cross-linking process neither
disrupts the structure of the micelles nor promotes inter-micelle cross-linking. Aqueous
solutions of cross-linked micelles (0.25 mg/mL) were cast on copper grids and imaged by
TEM. Micelles observed by TEM supported the DLS data, with an average micelle
diameter of 26 ± 4 nm (Figure 3.7B). The micelles imaged by TEM appeared as
spherical structures and were dispersed cleanly on the substrate.
Cross-linked micelle solutions were stable, as characterized by DLS, to
concentrations well below the CMC (0.01 mg/mL). However when treated with 5 mM
dithiothreitol (DTT) at 37 °C, then cooled to room temperature and analyzed again by
DLS, no signal was detected (as for the uncross-linked polymer at the same
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concentration) indicating complete dissolution of the polymer micelle by disruption of
the disulfide cross-links (Figure 3.7C).
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Figure 3.7 (A) Percent decline of free thiol over time for micelles prepared from
copolymer 55B, monitored by Ellman's test; (B) TEM of cross-linked micelles formed
from polymer 55B; (C) DLS of cross-linked polymer micelles from copolymer 55A
below the CMC (0.01 mg/mL) (left), and DLS of the same sample after treatment with
DTT (right); DTT cleavage of disulfide linkages gives free polymer in solution (below
CMC).
These redox-sensitive core cross-linked PC polymer micelles comprise a
potentially suitable delivery platform for therapeutics, in which a triggered release can
enable selective and targeted delivery of a drug, as the cytosol and nucleus are known to
have a significantly higher reducing potential (mM) than the extracellular fluids (μM). 66
CPT was used as the chemotherapeutic, specifically a pyridyl disulfide-functionalized
CPT derivative, prepared similarly as reported in the literature,71 to facilitate conjugation
to the polymer by disulfide formation. Briefly, 3-(2-pyridyldithio)-propionic acid (56)
was prepared by reaction of 2,2'-dithiodipyridine with 3-mercaptopropionic acid in ethyl
acetate, and purified by column chromatography on silica gel to yield the desired product
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in 95 % yield.77 Carbodiimide coupling of camptothecin (1) and linker 56 was achieved
in anhydrous methylene chloride71 (Figure 3.8).

Following purification by column

chromatography on silica gel, eluting with methanol/methylene chloride mixtures,
camptothecin derivative 57 was obtained as a yellow solid in ~50 % yield. The structure
was confirmed by NMR spectroscopy and high resolution mass spectrometry (calculated,
546.115; found, 546.113).
CPT-pyridyl disulfide 57 was conjugated to polyMPC-DHLA by stirring in a 2:3
mixture of MeOH/DMSO for 72 hours at 37 °C. The solution was dialyzed against
methanol (MWCO 1,000) to remove unreacted 57, then against water to induce micelle
formation. After complete removal of the organic solvents, the aqueous solution was
transferred to a vial and purged with air to form CPT-loaded core-cross-linked polymer
micelles, as depicted in Figure 3.8.

CPT loading was characterized by UV/Vis

spectroscopy, comparing absorbance at 370 nm with a CPT solution of known
concentration. Polymer-CPT prodrugs prepared in this way achieved from 5 to 10 wt %
CPT-loading.

Figure 3.8 Synthesis of CPT-pyridyl disulfide 57, conjugation to polyMPC-DHLA
copolymer to give prodrug 58, subsequent cross-linked micelle formation, and
characterization of CPT loading by UV/Vis spectroscopy.
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CPT release from the polymer micelles was monitored by dialysis, where 1 mL of
micelle solution was transferred to a cassette (MWCO 3,500), and dialyzed against PBS,
or PBS + 3 mM DTT (300 mL), in a closed container at 37 °C. At select time points,
aliquots were removed from the external medium, and replaced with fresh buffer, while
monitoring fluorescence intensity at 440 nm over time (λex = 370 nm). Free CPT was
dialyzed against PBS to demonstrate that diffusion out of the dialysis cassette is not a
limiting factor, and to establish a benchmark for assessing the performance of the
micelle-based systems. CPT (without encapsulation) diffused through the cassette within
6 hours, with 90 % released in the first 2 hours (Figure 3.9). For further comparison,
polymer micelles were prepared containing unmodified CPT simply encapsulated in the
core (i.e. having no disulfide linkage). Physically encapsulated systems showed little
difference from CPT alone, with an initial burst release of 75 % in 4 hours, followed by
slow release of the remaining drug over two days. In contrast, the disulfide-conjugated
CPT prodrug micelles showed much different release profiles. In PBS containing DTT (3
mM), CPT release was fast, with 50 % release in 5.5 hours, and complete release in 2
days. In PBS at pH 7.4, CPT release was slow (85 % over 5 days), presumably due to
slow hydrolysis of the ester linkage, with a half-life (t1/2) of 28 hours. These results
suggest these polyMPC-CPT prodrug micelles as a potential drug delivery system that is
relatively stable in a neutral environment, yet can exploit the redox characteristics of the
intracellular environment.
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Figure 3.9 Release profiles of CPT, encapsulated CPT, conjugated CPT in PBS, and
conjugated CPT in PBS + 3 mM DTT. Samples were analyzed in triplicate; error bars
represent ± standard deviation.
The cytotoxicity of poly(MPC-DHLA)-CPT conjugates was tested in vitro against
human breast cancer (MCF7) and colorectal (COLO205) adenocarcinoma cells by Dr.
Sangram Parelkar.

This was done by incubating CPT-equivalent concentrations of

poly(MPC-DHLA)-CPT conjugates with these cells for 72 hours, followed by cell
viability measurements using a luminescence plate reader. Dose response curves (Figure
3.10) showed that micellar conjugates (with CPT loadings of 2 and 5 weight percent)
were potent against the cancer cell lines tested. The observed cytotoxicity arises from
released CPT (a result of ester bond cleavage), and the polymer itself exhibits no toxicity
even at extremely high concentrations (2.5 mg/mL).
The half-maximal inhibitory concentration (IC50) values of poly(MPC-DHLA)CPT prodrug micelles were in the range of 3-9 μM, as shown in Table 3.3, where the
comparable IC50 values for both poly(MPC-DHLA)-CPT conjugates originate from their
similar release rates.

The data shows poly(MPC-DHLA) micelles containing CPT

conjugated by disulfide linkage induce toxicity at higher concentrations than CPT alone.
This is expected for polymer prodrugs, and is a key feature that allows higher maximum
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tolerated dose (MTD) of prodrugs in vivo.78,79 Interestingly, CPT that was physically
encapsulated within the micelles (i.e. no covalent linkage) showed nearly identical
toxicity to native CPT. This is likely due to the fast release observed for these structures,
as compared to the gradual release of CPT from the prodrugs. The combination of redox
triggered release and the cell culture data presented here will be beneficial for controlling
drug release in vivo, while exploiting the very high water solubility arising from the
phosphorylcholine-substituted polymer.
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Figure 3.10 In vitro cytotoxicity of (A) polyMPC-DHLA micelles, and of CPT-loaded
polyMPC-DHLA micelles with (B) human breast (MCF7) and (C) colorectal (COLO205)
cells. Error bars represents ± standard deviation.
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Table 3.3 IC50 values of poly(MPC-DHLA)-CPT micelles in MCF7 and
COLO205 cancer cell lines.
IC50 [μM]

MCF7

COLO 205

CPT

0.51 ± 0.05

0.43 ± 0.1

Poly(MPC-DHLA)-CPT (encapsulated)

0.48 ± 0.01

0.44 ± 0.1

Poly(MPC-DHLA)-CPT (2 wt %)

3.0 ± 1.8

8.3 ±0.8

Poly(MPC-DHLA)-CPT (5 wt %)

3.6 ± 0.8

4.7 ± 0.3

In summary the synthesis of novel diblock copolymers and micelles based on
phosphorylcholine and dihydrolipoic acid-containing methacrylates was shown, as well
as their potential utility as a drug delivery platform. Use of DHLA as the hydrophobic
block allows for post-polymerization conjugation and cross-linking reactions by disulfide
formation.

CPT was successfully conjugated to the DHLA block, then released in a

controlled manner in buffer, with the benefit of a trigger in a reducing environment. The
CPT-loaded micelles demonstrated cytotoxicity at higher CPT concentrations than with
the drug alone, as expected for polymer prodrugs due to the covalent connection of CPT
to the backbone. The combination of robust, highly water soluble micelles and stimuliresponsive drug release yields a system that is promising for overcoming challenges
faced by micellar delivery vehicles, including in vivo stability and fast, non-specific
release of their contents.
3.5 PolyMPC-DOX prodrugs
Doxorubicin (DOX) is another example of a clinically relevant chemotherapy
agent that can benefit from a polymer-based delivery platform.
intercalator, affecting a wide range of DNA processes.

DOX is a DNA

As is the case with many

chemotherapeutics, the potent anticancer activity of DOX is accompanied by undesirable
side effects. Doxil, a PEGylated liposomal formulation of DOX, has shown favorable
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pharmacokinetics compared to the free drug, as well as reduced dose-limiting
toxicity.80,81

Despite the benefits of this formulation, Doxil suffers from its own

toxicities, especially palmer-planter erythrodysesthesia and mucositis/stomatitis arising
from accumulation in the skin.82-85 Covalent polymer-drug conjugation has also been
explored with DOX, including a PEGylated dendrimer at a drug loading of 10 weight
percent, showing promise in preclinical studies.14 In addition to the degradable dendritic
structures,14,86 HPMA,87-89 and PEO-based polymers90 were also conjugated to DOX
exploiting pH-sensitive hydrazone chemistry. The use of an acid-labile linker enables
specific release of DOX either in the slightly acidic environment of tumor tissue91,92 or
intracellularly in the acidic environments of the endosomal or lysosomal compartments.93
In 2012, Dr. Xiangji Chen, a post-doctoral researcher in the Emrick research
group, reported the synthesis of polyMPC-DOX conjugates, prepared by integrating
hydrazone linkages as pendent groups along the polymer backbone.94 Such structures
were prepared by ATRP copolymerization of MPC with either 2-tert-butoxy-2-oxoethyl
methacrylate (TBOEMA) or 2-ethoxy-2-oxoethyl methacrylate (EtOEMA) using copper
bromide and bipyridine as the catalyst and ligand, respectively. The ethyl esters of
copolymer 60 are readily converted to acyl hydrazides by substitution with hydrazine to
give polyMPC-hydrazine, shown as polymer 61 in Scheme 3.1.

Polymer 61 was

characterized by aqueous gel permeation chromatography (GPC) against linear PEO
standards and by 1H NMR spectroscopy to determine the mole percent of hydrazine
monomer units within the polymer. Polymer 61 was conjugated to DOX by hydrazone
formation in methanol, in the presence of magnesium sulfate and acetic acid, to give
polyMPC-DOX prodrug 62.

PolyMPC-DOX 62 was purified by preparative size
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exclusion chromatography, and lyophilized to give a bright red powder, which proved
stable for months when stored as a dry solid at -20 °C.
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Scheme 3.1 Synthesis of polyMPC-DOX conjugate 62 from ethyl ester-containing
polyMPC precursor polymer 60.
The synthesis towards polyMPC-DOX prodrugs described by Chen et al94 results
in conjugates with exceptionally high water solubility and tunable drug loading, reaching
or exceeding 30 weight percent DOX. These polyMPC-DOX conjugates displayed pH
sensitive release profiles, with half-life (t1/2) values ranging from 2-40 hours at pH 5.0,
while only 2 to 20 % of DOX was released in 48 hours at pH 7.4. In cell culture, the
half-maximal inhibitory concentration (IC50) values for polyMPC-DOX ranged from 1.5 16 μM for human breast cancer (MCF7 and MDA-MB-231) and colorectal (COLO 205)
adenocarcinoma cell lines.94

Moreover, the maximum tolerated dose (MTD) was

determined for polyMPC-DOX in athymic Nu/j mice, and was found to be well-tolerated
to over 30 mg/kg over the course of the 30 day study; mice which received doses of 50
mg/kg showed only a 10 % weight loss at 22 days. These values represent an increase
compared to the MTD of free DOX (~6 mg/kg),95 the liposomal formulation DOXIL(36
mg/kg)14 and a PEGylated polyester dendritic DOX example (20-40 mg/kg).14
The work presented in this thesis aims to extend in vivo prodrug characterization
to include pharmacokinetics, biodistribution, and treatment efficacy data for polyMPCDOX using a 4T1 murine breast cancer model in collaboration with Dr. Sallie Schneider
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at the Pioneer Valley Life Sciences Institute (PVLSI) (Molecular Pharmaceutics, 2014).
The 4T1 mammary carcinoma was selected as an extremely aggressive breast cancer
model that is highly tumorigenic and metastatic, and thus can be considered as a model
for triple negative breast cancer.96,97

Unlike many tumor models, 4T1 tumors can

metastasize spontaneously from the primary tumor to multiple distant sites including the
lungs, lymph nodes, liver, brain and bone within weeks following injection.96 We viewed
the 4T1 model as a challenging tumor model to test the effect of polyMPC-DOX
prodrugs, potentially enhancing the utility of DOX in late stage breast cancer. 4T1 cells
can be introduced orthotopically by direct injection into the mammary gland, such that
the primary tumor site is anatomically correct, and the syngeneic nature of the cells
allows for use of immuno-competent animals, and thus examination of the effects of
polyMPC-DOX conjugates on the immune system. The 4T1 breast cancer model has
been used by others to study polymer prodrugs in vivo, including paclitaxel,98,99
docetaxel,98 cisplatin,100,101 gemcitabine,102 and doxorubicin103,104 with variable success
with respect to slowing tumor growth and reducing off-target toxicity. Given the high
level of water solubility and degree of drug loading achievable with polyMPC-DOX,
these prodrugs have potential for the treatment of breast cancer, and this study
demonstrates their efficacy in 4T1 tumor-bearing mice.
3.6 Efficacy of polyMPC-DOX in 4T1 tumor-bearing mice
For the efficacy study described here, we used polyMPC-DOX with an estimated
molecular weight of 25,000 g/mole, and DOX loading of 22 weight percent. To further
extend our in vivo prodrug characterization, the pharmacokinetic profile of polyMPCDOX was evaluated in BALB/c mice. Animals were sorted into three groups of eight,
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with a control group (HBSS), a free DOX group, and a polyMPC-DOX group (6 mg/kg
DOX equivalent doses) introducing drugs by a single tail vein injection of 100 μL total
volume. Blood serum levels of DOX were monitored over time, analyzing for the
presence of drug by HPLC equipped with a fluorescence detector. As shown in Figure
3.11, free DOX concentration decreased rapidly, with a t1/2 of 15 minutes, clearing to
near-undetectable levels within 1 hour.

This is consistent with reported values for

DOX.95,103 PolyMPC-DOX displayed a significantly longer circulation half life of 2
hours. Accordingly, the area-under-the-curve (AUC) was dramatically higher for the

DOX Concentration (ug/mL)

polyMPC-DOX prodrug (408 μg•h/ml) compared to free DOX (22 μg•h/ml).
80
70
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Figure 3.11 Pharmacokinetic analysis of polyMPC-DOX in BALB/c mice.
Polymer conjugation extends the circulation half life from 15 minutes to 2 hours and
increases the AUC from 22 μg•h/ml to 408 μg•h/ml . Error bars represent ± standard
deviation.
The biodistribution of DOX was determined for both the free drug, and polyMPCDOX, three and five days post-injection from the 6 mg/kg DOX equivalent doses
administered to the tumor-bearing mice used in the PK study (Figure 3.12). The tumor
uptake of DOX for polyMPC-DOX was 700 ng per gram of tissue three days after
injection, and 390 ng/g five days after injection. This represents a two-fold increase over
free DOX at Day 3 (350 ng/g) and a three-fold increase over free DOX at Day 5 (130
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ng/g). Moreover, polyMPC-DOX conjugates displayed reduced accumulation in offtarget organs, including the spleen and especially the lungs relative to free DOX.
Significantly higher drug accumulation was noted in the liver for the polyMPC-DOX
group compared to the free DOX group, which we attribute to the prolonged circulation
times and delayed clearance noted for the polymer prodrug. While DOX is known to be
metabolized primarily by the liver, the liposomal formulation DOXIL was found to have
impaired hepatic metabolism, suspected to be excluded from uptake based on liposome
size.105 Similarly the increased size of polyMPC-DOX prodrugs relative to free DOX
may hamper hepatic uptake, resulting in delayed accumulation. Low drug accumulation
found in the heart for the polyMPC-DOX group is potentially advantageous, reducing
cardiotoxicity effects, a known dose-limiting side effect commonly associated with DOX
administration.81 Tumor-to-normal tissue distribution ratios are given in Table 3.4,
highlighting the preferential DOX uptake in tumor tissue relative to healthy tissue. The
benefits of passive tumor targeting of polymer prodrugs has been noted before, and the
data presented here suggests the polyMPC-DOX has similar benefits in vivo.4,103
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Figure 3.12 Biodistribution analysis of polyMPC-DOX compared to free DOX after (A)
3 days and (B) 5 days expressed as ng DOX / g tissue. The significance was determined
using a two-tailed Student's t-test [* p=0.05 to 0.01; ** p=0.01 to 0.001; *** p<0.001].
Error bars represent ± the standard error of the mean (SEM).
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At the conclusion of the PK and biodistribution study, the spleen, liver, kidney,
heart, lungs, and tumors were removed from the animals and weighed, with livers and
spleens fixed and paraffin-embedded for histological analysis.

As shown in Figure

3.13A, only small differences amongst the groups were noted with respect to tissue
weights. Histological analysis of tissue sections stained with hematoxylin and eosin
(H&E) suggested no significant off-target toxicity at these high levels of DOX, consistent
with the use of the polyMPC as a carrier. Despite the previously noted increase in drug
accumulation in the liver, H&E analysis revealed no sign of adverse effects or off-target
toxicity in the liver (Figure 3.13B).
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Table 3.4 Tumor-to-normal tissue distribution ratios for polyMPC-DOX and DOX.
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While our data, and other literature reports on polyMPC point to the safety of its
use in vivo, we are not aware of prior reports that examine potential in vivo
immunogenicity arising from its presence in the bloodstream. Thus, in conjunction with
these in vivo efficacy studies, we also sought to gauge whether there were innate or
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adaptive immune system responses to polyMPC, accomplished through a complete blood
count (CBC), and measurement of cytokine responses by an enzyme-linked
immunosorbent assay (ELISA) (Figure 3.14). Analysis of serum cytokine and white
blood cell (WBC) levels indicated an initial increase in total WBC count on Day 3 with
polyMPC DOX (Figure 3.14A), with no differences noted on Day 5 (Figure 3.14B). The
initial increase in white blood cell count, suggestive of a foreign antigen response, was
rectified by Day 5. Red blood cell (RBC) counts indicated no differences across the
treatment groups. Furthermore, we observed no significant differences between
polyMPC-DOX and HBSS in Th1 versus Th2 cytokines by ELISA at Day 3, with only a
slight decrease in IL12 and IL10 noted at Day 5. However, this cannot be attributed to the
polyMPC carrier, since this decrease is much more pronounced in the case of animals
treated with free DOX (Figures 3.14C-3.14H). These results suggest that polyMPCbound DOX does not elicit significant adverse immunogenic effects that could lead
towards undesired anemia or inflammatory response in animals.
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blood count (CBC) and ELISA cytokine measurements three and five days after
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injection. (A) White blood cell count (WBC) (Day 3); (B) WBC (Day 5); (C) Interferon-γ
(IFN- γ) (Day 3); (D) IFN- γ (Day 5); (E) Interleukin-12 (IL-12) (Day 3); (F) IL-12 (Day
5); (G) Interleukin-10 (IL-10) (Day 3); (H) IL-10 (Day 5). Error bars represent ± SEM.
4T1 tumor-bearing mice were used to evaluate the therapeutic performance of
polyMPC-DOX conjugates for the treatment of breast cancer. Tumors were established
by orthotopic injection of murine 4T1 cells (5 x 106 4T1 cells in Hank's balanced salt
solution, HBSS) into the mammary fat pad of the mice (~17.5 g, 4 weeks old). The mice
were randomized into three groups of 15; at a tumor volume in the range of 42-132 mm3,
mice were administered either HBSS, free DOX (3 mg/kg, ~1/2 MTD), or polyMPCDOX (15 mg/kg DOX equivalent, ~1/2 MTD) by tail vein injection. Subsequent doses
were administered on Days 7 and 17 (polyMPC-DOX group only). Mice were examined
and weighed every 2-4 days, and tumor volume was determined by caliper measurements
(calculated by 0.52 x L x W2) over a period of 29 days. Mice were removed from the
study when the tumor volume reached 1500 mm3, if weight loss exceeded 20 %, or if the
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animal appeared to be showing signs of stress, including a scruffy appearance or
abnormal behavior. A summary of tumor efficacy results is presented in Figure 3.15.
Figure 3.15A shows that survival was increased substantially for mice receiving
polyMPC-DOX compared to both the untreated and free DOX-treated mice. Notably,
mice receiving the free DOX treatment showed no improvement, essentially mirroring
results for the HBSS group; all these mice were removed from the study by Day 18. In
contrast, 80 % of the mice receiving the polyMPC-DOX treatment remained in the study
at Day 18, with overall survival in the polyMPC-DOX group extended almost two-fold
(29 days) compared to the other treatment groups. Figure 3.15B shows that tumor growth
was greatly suppressed in the mice receiving the polyMPC-DOX, whereas the mice
receiving free DOX showed no difference relative to the untreated mice. Untreated and
free DOX treated mice surviving to Day 18 displayed tumors with average volumes
ranging from 1600-1850 mm3, requiring their removal from the study. PolyMPC-DOX
treated mice at Day 18 had average tumor volumes of 1050 mm 3, and at the Day 29 endpoint, average tumor volume was 1170 mm3. The weights of the mice overall remained
largely unchanged over the course of the study, as shown in Figure 3.15C. However,
following the third dose of polyMPC-DOX, animal weights did not return to normal
range quickly enough, necessitating their removal from the study. At the conclusion of
the study, tissues (livers, spleens, hearts, kidneys) were collected and analyzed to
compare to the results obtained from the PK/biodistribution study, with the efficacy mice
displaying comparable tissue weights amongst treatment groups, with the exception of
the lungs. The significant weight increase in the lungs of the polyMPC-DOX group is
attributed to the numerous metastases in the lungs, likely due to the prolonged survival of
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the mice in this group (two times that of the free DOX and HBSS mice). We note that
the mice receiving polyMPC-DOX treatment were dosed below the previously
determined MTD for these conjugates (30-50 mg/kg DOX equivalent) so that the
cumulative dose received did not exceed the MTD. Since the PK data reveals that
polyMPC-DOX is nearly cleared within 48 hours, future animal studies will examine a
more frequent dosing regimen, aiming towards complete tumor regression. Nonetheless,
this experiment confirms the efficacy of polyMPC-DOX prodrugs, even when presented
with aggressive, highly metastatic 4T1 cancer in live animals.
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Figure 3.15. Summary of efficacy data in 4T1 mouse model. (A) Survival curve for
mice treated with HBSS (squares, solid line), polyMPC-DOX (triangles, dashed line),
and free DOX (inverted triangles, dotted line); (B) tumor growth over time for mice
treated with HBSS (squares, solid line), polyMPC-DOX (triangles, dashed line), and free
DOX (inverted triangle, dotted line); (C) mouse weight for mice treated with HBSS
(squares, solid line), polyMPC-DOX (triangles, dashed line), and free DOX (inverted
triangle, dotted line) Arrows indicate days on which treatments were administered: 0, 7,
and 17 (polyMPC-DOX only). Error bars represent ± SEM.
The present study demonstrates the ability of polyMPC-DOX to prolong
circulation half-life from 15 minutes to 2 hours, with favorable accumulation occurring in
the tumor as opposed to healthy tissues, and no significant innate or adaptive
immunogenic responses. Moreover, we demonstrate the efficacy of polyMPC-DOX in
4T1 tumor-bearing mice, increasing the overall survival two-fold, and significantly
reducing tumor growth in mice. The aggressive 4T1 mouse model reveals the potential
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for polyMPC-DOX in the treatment of triple negative breast cancer, and ongoing studies
include evaluating the in vivo efficacy against a human breast cancer cell line.
3.7 Conclusions and Future Outlook
PolyMPC has been demonstrated as an effective drug carrier for small molecule
chemotherapeutic agents, with camptothecin and doxorubicin as examples.

Using

appropriately functionalized comonomers with MPC, drugs can be incorporated along the
polymer backbone as pendent groups, a strategy which has allowed for unprecedented,
massively high drug loadings, for example up to 45 weight % in the case of DOX.
Furthermore, the mechanism of release can be tailored according to the linker, including
through simple hydrolysis, or according to environmental (i.e. intratumoral or
intracellular) triggers including redox or pH sensitivity.
Future studies will include the further exploration of more advanced architectures,
for example, polyMPC-based micelles.

Polymer micelles provide a route to larger

structures (20 - 100 nm in diameter), enhancing the circulatory retention and thus
therapeutic window. Additionally, active targeting strategies will be employed, aiming to
reduce non-specific uptake by healthy tissue and reduce off-target toxicity. To realize
this synthetically, the antibody Erbitux (Cetuximab), known to target the epidermal
growth factor receptors (EGFR) that are typically upregulated in tumors, will be used.
Antibody-polyMPC conjugation can be accomplished through installing a thiol-reactive
polymer chain end, such as maleimide. Antibody-polymer prodrug conjugates have the
added benefit of high drug loading; in addition to incorporating multiple copies of drug
along the polymer, multiple polymer chains (usually between 4 and 8) can be conjugated
to a single antibody.
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CHAPTER 4
PROMOTING CELL ADHESION ON SLIPPERY PHOSPHORYLCHOLINE
HYDROGEL SURFACES
4.1 Introduction
Hydrogels are three-dimensional cross-linked polymeric materials capable of
absorbing and retaining large amounts of water. This "water-rich" environment makes
hydrogels suitable for biological applications, while the mechanical tunability of the
polymer component gives substantial breadth to these materials.

Hydrogels from both

natural and synthetic polymers are of interest for drug delivery,1-4 sensors5-7 and tissue
engineering,8-11 where tuning the chemistry tailors the materials towards desired
applications. Synthetic polymer hydrogels are commonly prepared by conventional free
radical polymerization, in which a small percentage of difunctional monomer leads to
cross-linking. Newer gelation methods have been developed with the advent of "click
chemistry",12 for example exploiting copper-catalyzed azide-alkyne cycloaddition13,14
and thiol-ene reactions.15,16
Synthetic polymers commonly utilized as hydrogels for biomaterials include
poly(ethylene glycol),17-20 poly(hydroxyethyl methacrylate),21,22 poly(vinyl alcohol),23,24
and poly(acrylamide).25,26 Phosphorylcholine (PC)-based polymers are of growing
interest as biomaterials, since the zwitterionic pendent groups in these polymers impart
exceptional hydrophilicity and biocompatibility. PC-polymer hydrogel membranes were
introduced by Nakabayashi and coworkers,27 consisting of a copolymer of 2methacryloyloxyethyl phosphorylcholine (MPC) and n-butyl methacrylate. Additional
examples include MPC hydrogels prepared by conventional radical polymerization with
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various difunctional cross-linkers,28 a novel PC-dimethacrylate cross-linker that produces
cross-linked MPC hydrogels,29,30 degradable PC hydrogels containing phosphoester
linkages,31 PC hydrogels that gel by hydrogen bonding interactions,32 a boronic acidcontaining PC copolymer hydrogel for 3-D cell encapsulation,33 and our prior work on
PEG-PC hydrogels with tunable mechanical properties.34 PC-based hydrogels are also
used in contact lenses, with several examples of siloxane-containing PC hydrogels
reported.35-37 This thesis sought to improve upon the PC-polymer scaffold by exploiting
new chemistries and mild gelation conditions, while promoting cell interactions with
these conventionally non-adherent (‘slippery’) biomaterials, making them attractive for
future applications in 3-dimensional cell culture.
The new MPC-containing polymers reported in this thesis work utilize a lipoic
acid-containing methacrylate and a GRGDS (glycine-arginine-glycine-aspartic acidserine) substituted methacrylamide for copolymerization with MPC. Incorporation of the
lipoic acid comonomer gives access to dihydrolipoic acid (DHLA) moieties in the
polymer structure, which allows for facile post-polymerization cross-linking with
poly(ethylene glycol)diacrylate (PEGDA) by Michael addition between the alkenes and
the thiols of DHLA, precluding the need for initiators or other additives. The reaction of
thiols with the electron-deficient olefins of acrylates occurs rapidly at slightly basic pH,
and we observed fast hydrogel formation (<10 minutes) from these components. The
GRGDS peptide, a minimal cell adhesion sequence found in extracellular matrix (ECM)
proteins, permits mammalian cell attachment to the ECM by cell adhesion receptors
(integrins).38 Using C2C12 and SKOV3 cells, known to express RGD interacting α5β1 and
αvβ3 integrins,39-41 we demonstrate that the incorporation of the GRGDS peptide sequence
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into the hydrogel permits specific cell adhesion,42 with a notable effect of peptide
concentration on cell attachment, spreading and proliferation (Journal of Materials
Chemistry B, 2014).43
4.2 Synthesis of cross-linkable polyMPC for hydrogels
Phosphorylcholine (PC)-based hydrogel precursor polymers were prepared
according to Scheme 4.1, by incorporating monomer 51 into random copolymer
structures, providing a synthetic handle for efficient cross-linking. Esterification of 2hydroxyethyl methacrylate (HEMA) with lipoic acid (LA), using EDC coupling, gave
HEMA-LA monomer 51 as a yellow oil.44 Compound 51 was characterized by 1H NMR
spectroscopy, specifically noting the vinyl protons at 5.4 and 6.1 ppm, and the
characteristic signals from the lipoic acid moiety in the alkyl region of the spectrum (~2.5
ppm). A GRGDS-containing methacrylic monomer was prepared by Fmoc-protected
solid phase peptide synthesis (SPPS) for the purpose of promoting cell adhesion and
enhancing the utility of these PC-containing hydrogels as biomaterials.

GRGDS

methacrylamide 63 was prepared on a 2-chlorotrityl chloride resin, by coupling with
serine, followed by reactions with aspartic acid, glycine, arginine and glycine. The final
glycine coupling was followed by an N-Fmoc-amidocaproic acid linker, then capped with
methacrylic acid.

Simultaneous side-chain deprotection and resin-cleavage, using a

solution of trifluoroacetic acid/H2O/triisopropylsilane, gave GRGDS-methacrylamide
monomer 63 as a white solid in 50 % yield after precipitation from ether. The structure
of the GRGDS monomer was confirmed by 1H and

13

C NMR spectroscopy, as well as

electrospray ionization mass spectrometry (calculated: 672.3, found, 672.4).
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Scheme 4.1 Synthesis of GRGDS-methacrylamide 63 by solid phase peptide synthesis
and copolymerization with MPC and HEMA-LA to give copolymer 64.
Copolymerization of MPC, HEMA-LA, and GRGDS-MA was carried out using
conventional free radical polymerization with azobisisobutyrylnitrile (AIBN) as the
initiator in a methanol/dimethylsulfoxide solution at 65 °C (Scheme 4.1). Monomer
conversion generally reached >95 % within 4 hours, as judged by 1H NMR spectroscopy,
comparing the integration of the monomer vinyl peaks at 5.4 and 6.1 ppm with the
polymer backbone methyl protons at 1.0 ppm. The copolymers were precipitated from
THF, and further purified by passing over a short silica column eluting with methanol.
The lipoic acid-containing copolymers were reduced to the free thiol form with NaBH4 in
water (4 molar equivalents relative to lipoic acid). The reaction was complete in 2 hours,
at which point the solution pH was adjusted to ~3 with HCl(conc). Purification by dialysis
(MWCO 1000) followed by lyophilization afforded copolymer 64, poly(MPC-co-DHLAco-GRGDS), as a white solid in 80 % yield. The polymers were characterized by
aqueous gel permeation chromatography (GPC) (0.1 M NaNO3 + 0.02 wt % NaN3)
relative to linear poly(ethylene oxide) standards, giving number-average molecular
weights ranging from 40 to 65 kDa, with molecular weight distributions typical of free
radical polymerization (Figure 4.1). DHLA incorporation (~20-30 mole percent) was
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characterized by 1H NMR spectroscopy, and found to match closely with comonomer
feed ratio, shown in Table 4.1. GRGDS content was adjusted from 0.25 to 5 mole
percent by changing the feed ratio of the GRGDS-methacrylamide. While precise
quantification of oligopeptide incorporation is difficult to perform spectroscopically,
quantitative monomer conversion (as confirmed by 1H NMR spectroscopy) suggested
that the target copolymer composition was achieved. The copolymers maintained good
water solubility (>100 mg/mL) even at relatively high DHLA content and at high
molecular weight, highlighting the exceptional hydrophilicity of the phosphorylcholine
moiety and its ability to solubilize these multifunctional copolymers.
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Figure 4.1 A) Aqueous GPC and B) 1H NMR spectroscopy (in MeOD) of poly(MPC-coDHLA).

Table 4.1 Summary of polymerization results for poly(MPC-co-DHLA-co-GRGDS).
Sample

Theoretical MW
(g/mole)

Mn (g/mole)

PDI

% DHLA

% GRGDS

64A
64B
64C
64D

14,500
12,300
12,500
13,400

64,200
48,100
54,400
42,200

4.4
5.2
4.6
4.7

21 %
24 %
29 %
27 %

0%
0.25 %
1%
5%
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4.3 Preparation of polyMPC hydrogels by Michael addition
Hydrogels containing polymer 64 formed readily under slightly basic conditions
(pH 9 sodium borate buffer), using PEGDA as a difunctional cross-linker in a 1:1 molar
ratio of thiol:acrylate (Scheme 4.2). We emphasize that the PC-polymers allow for
simple, initiator-free gelation in a completely aqueous environment, in contrast to many
hydrogels that require external initiators, and sometimes organic solvents, which must be
removed prior to their use in a biological setting. Upon addition of PEGDA to DHLAcontaining polyMPC, gelation in pH 9 buffer occurred in <10 minutes at 37 °C. We note
that no gelation was observed in the absence of PEGDA, confirming cross-linking occurs
by Michael addition and not interchain disulfide formation of polyMPC-co-DHLA.
n

m

p

n

n

m

p

5

pH 9 Na borate buffer
37 C

64

n
n

65

Scheme 4.2 Preparation of hydrogels, represented as polymer 65, by mixing PEGDA at
37 °C in pH 9 sodium borate buffer.
The equilibrium water content (EWC) of the hydrogels was analyzed by soaking
the gels in water to equilibrate the swollen state, and remove any uncross-linked material.
After three days, excess water was removed and the weight of the swollen hydrogel was
compared to that of the dried hydrogel. These polyMPC hydrogels are very water-rich
(>90 % water by weight), with no significant EWC variation observed for samples
prepared from PEGDA cross-linkers of different molecular weight, and having different
GRGDS peptide content (Figure 4.2). The water uptake of PC hydrogels is much higher
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than that of many PEG-based examples,4,10,19 highlighting the exceptional properties of
the PC zwitterion.

D) 100
A)

B)

90

C)

80

EWC (%)

70
60
50
40
30

1 cm

20
10
0

1

2

3

Figure 4.2 PolyMPC-co-DHLA and PEG2000DA: (A) before gelation and (B) hydrogel
formation after 10 minutes of heating at 37 °C. Hydrogels were cut into 1 cm disks (C)
and used to analyze equilibrium water content (EWC, %). (D) EWC of polyMPC
hydrogels: (1) hydrogel cross-linked with PEG700DA (91.3 ± 0.2 %); (2) hydrogel crosslinked with PEG2000DA (93.2 ± 1.5 %); (3) GRGDS-containing hydrogel cross-linked
with PEG2000DA (97.6 ± 0.2 %). Samples were measured in triplicate and error bars
represent ± standard deviation.
Dynamic mechanical analysis (DMA) and shear rheology were used to probe the
mechanical properties of swollen hydrogels (Figure 4.3). After swelling for 48 hours, a
test of the frequency response using DMA was performed, showing a constant elastic
modulus (G') of 2.95 ± 0.16 kPa throughout the measured frequency range, with the
elastic modulus always greater than the loss modulus (G"; 0.27 ± 0.16 kPa).
Furthermore, rheology experiments indicated the potential for mechanical tunability of
this system: as expected, increasing polymer concentration or molecular weight led to
greater elastic modulus of the resulting hydrogels, illustrating the range of
physical/mechanical properties accessible through this materials chemistry.
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Figure 4.3 (A) Dynamic mechanical analysis (DMA) frequency response experiment of
hydrogels prepared from polyMPC-co-DHLA (100 mg/mL), cross-linked with
PEG700DA. (B) Shear rheology experiments demonstrate the effect of varying polymer
component molecular weights on the elastic modulus (G'). Sample 1: polyMPC-coDHLA (60 kDa) with PEG6000DA; Sample 2: polyMPC-co-DHLA (25 kDa) with
PEG6000DA; Sample 3: polyMPC-co-DHLA (25 kDa) with PEG700DA.
4.4 In vitro cell culture: Evaluating cell adhesion
We next examined the influence of the GRGDS sequence on polymer-cell
interactions, using hydrogels prepared in 24-well tissue culture plates. Stock solutions of
both polymer and cross-linker were prepared in pH 9 sodium borate buffer, then mixed in
the plate at a 1:1 ratio of [SH]:[acrylate], with a final polyMPC concentration of 50
mg/mL. The plate was incubated at 37 °C for 20 minutes to ensure effective gelation.
The resulting hydrogels were washed/exchanged with PBS to remove the borate buffer.
The hydrogels were then washed twice in sterile cell culture growth medium, and
incubated for 2 hours at 37 °C in 5 % CO2 to remove residual PBS and reduce nonspecific cell binding. The media was aspirated and the surface of the hydrogel seeded
with C2C12 or SKOV3 cells, followed by incubation at 37 °C; cell adhesion was
visualized using optical microscopy (Figure 4.4). Notably, cells seeded on polyMPC
hydrogels lacking the GRGDS peptide failed to attach, and at 24 hours were aggregated
in the media above the hydrogel, as seen in Figure 4.4A-B. In contrast, hydrogels
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functionalized with the GRGDS peptide sequence showed cell spreading and
proliferation on the hydrogel surface, similar to the control (polystyrene tissue culture
plate), with no floating cells observed (Figure 4.4C-H). C2C12 cells adhered to these
hydrogels relatively quickly (<6 hours), while SKOV3 cells adhered within 24 hours.
Increasing cell density was observed upon increasing GRGDS content from 0.25 % to 1
% to 5 % (corresponding to 0.4, 1.6, and 7 mM bulk GRGDS, respectively). Hydrogels
prepared from copolymer 64D, containing 5 % GRGDS, showed excellent cell spreading
and density, comparable to the polystyrene controls.
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Figure 4.4 Optical micrographs of C2C12 and SKOV3 cells after 24 hours incubation on
hydrogels from polymers containing (A-B) no GRGDS, (C-D) 0.25 % GRGDS, (E-F) 1
% GRGDS, (G-H) 5 % GRGDS, and on (I-J) polystyrene tissue culture plate. Scale bar =
100 μm.
Cell density was quantified using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega) 24 hours post cell-seeding.

The cell density measured for each

hydrogel is given as a percentage of the polystyrene control. For both C2C12 and SKOV3
cells, the density tracked with GRGDS peptide content. This is shown in the graph of
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Figure 4.5, in which cell density increased as a function of peptide incorporation, from
<50 % for 0.25 % peptide, to >90 % for 5 % peptide. The relative difference in cell
densities 24 hours after seeding confirms that the hydrogel surface permits cell
proliferation in addition to attachment, and that the GRGDS oligopeptide in the hydrogel
interacts with the cellular integrins.

Cell Density (%)

100

SKOV3
C2C12

80
60
40
20

0
-20
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Figure 4.5 Quantification of cell adhesion after 24 hours for C2C12 and SKOV3 cells,
expressed as percent cell density, on hydrogels containing no GRGDS (A), 0.25 %
GRGDS (B), 1 % GRGDS (C), and 5 % GRGDS (D), relative to the cell density in the
control (polystyrene tissue culture plate). Error bars indicate ± standard deviation.
4.5 Summary and future outlook
In summary, the synthesis of thiol-containing PC-polymers based on the
polymerization of MPC and HEMA-LA was described, with incorporation of GRGDSMA for cellular recognition. These polymers rapidly form hydrogels by Michael addition
to PEGDA in an initiator-free system at 37 °C in pH 9 buffer leaving no residual
initiators/additives after hydrogel formation. Mechanical properties testing suggests the
hydrogels as ideal materials for biological assays, capable of mimicking soft tissues or
tumor environments. PolyMPC and polyMPC-hydrogels, despite their excellent
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biocompatibility, are incapable of cell adhesion/proliferation on the hydrogel surface,
while hydrogels containing variable percentages of GRGDS promote cell adhesion and
proliferation, demonstrated using C2C12 and SKOV3 cells. Equipping these traditionally
‘slippery’ PC-polymers with such pronounced cell adhesion properties broadens the
scope of functional biomaterials available for developing more sophisticated in vitro and
in vivo applications.
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CHAPTER 5
EXPERIMENTAL SECTION
5.1 Materials
Pentafluorophenol, 4-(dimethylamino)pyridine (DMAP), triethylamine (TEA), N-(3dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride (EDC), 2-bromoisobutyryl
bromide, copper(I) bromide, 2,2´-bipyridine (bpy), bis-hydroxymethyl propionic acid,
oxalyl chloride, bis(pentafluorophenyl) carbonate, Grubbs' generation II catalyst, ethyl
vinyl ether, pyridine, lysozyme from hen egg white, 2-hydroxyethylmethacrylate
(HEMA), N-boc-aminooxy acetic acid, levulinic acid, ethylene glycol, trifluoroacetic
acid, methanol (anhydrous), dimethylsulfoxide (anhydrous), 4-hydroxybenzaldehyde,
sodium azide, N,N´-diisopropylethylamine (DIPEA), 2-bromopropionyl bromide, 6bromohexanoic acid, 2-[2-(2-chloroethoxy)ethoxy]ethanol, ethyl 2-bromoisobutyrate, 3(trimethylsilyl)propargyl alcohol, methacryloyl chloride, mouse serum, human plasma,
lipoic

acid,

3-mercaptopropionic

acid,

2,2'-dithiodipyridine,

4-cyano-4-

(phenylcarbonothioylthio)pentanoic acid, 4,4'-azobis(4-cyanovaleric acid) (ACVA),
ethyl bromoacetate, hydrazine monohydrate, acetic acid, magnesium sulfate, acetonitrile
(anhydrous), methacrylic acid, Fmoc-chloride, 6-aminocaproic acid, triisopropylsilane
(TIPS),

poly(ethylene

glycol)

diacrylate

(Mn

6,000,

2,000

and

700),

and

dimethylformamide (anhydrous) were purchased from Aldrich. 2-Methacryloyloxyethyl
phosphorylcholine (MPC) was purchased from Aldrich or synthesized according to
literature procedures. MPC purchased from Sigma Aldrich was washed with anhydrous
ether prior to use. Oxalyl chloride and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide)
(EDC) were purchased from TCI America.
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Ethylene chlorophosphate (COP) was

purchased from Alfa Aesar.

Camptothecin (CPT) and doxorubicin (DOX) were

purchased from 21CEC. HEMA and COP were purified by Kugelrohr distillation prior to
use.

Dichloromethane and triethylamine were distilled over calcium hydride and

tetrahydrofuran was dried over sodium/benzophenone ketyl and freshly distilled before
use. All other chemicals were used as received unless otherwise noted. EnzChek®
Lysozyme Assay Kit and Alexa Fluor 647 dye were purchased from Invitrogen. Prestained broad-range protein standards, 4-15 % Mini-Protean TGX precast gels, and BioSafe Coomassie stain were purchased from BioRad. Human colorectal (COLO205) and
breast (MCF7) adenocarcinoma cells were purchased from American Type Culture
Collection (ATCC). RPMI 1640 and MEM cell culture media were purchased from Life
Technologies and Mediatech, respectively. Fetal bovine serum (FBS) was purchased
from Atlanta Biologicals and bovine insulin from Aldrich. Cell viability was measured
using CellTiter-Glo luminescent cell viability assay from Promega. Dialysis cassettes
(MWCO 3,500; total volume 0.5-3 mL) were purchased from Fisher Scientific and
hydrated in water prior to use. Spectra/Por 3 dialysis membrane (MWCO 1000) was
purchased from Spectrum Laboratories, Inc. Sephadex (LH-20 and G-25) was purchased
from GE Life Sciences and swelled for 24 hours prior to use. Hank's Balanced Salt
Solution used for in vivo studies was obtained from Life Technologies (Gibco).
5.2 Instrumentation
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Brüker
Spectrospin DPX300, an Avance 400, or an Agilent 700. Aqueous GPC was performed in
0.1 M sodium nitrate and 0.02 weight percent sodium azide buffer against poly(ethylene
oxide) calibration standards, operating at 1.0 mL/ min with three Waters Ultrahydrogel

111

columns (7.8 x 300 mm) equipped with RI and UV/Vis detectors.

GPC in 1,1,1-

trifluoroethanol (TFE) (with 0.2 M sodium trifluoroacetate) was performed against
poly(methyl methacrylate) (PMMA) standards, operating at 0.75 mL/min at 40 °C with
three Agilent PL HFIPgel columns (300 x 7.5 mm) equipped with RI and UV/Vis
detectors.

UV/Visible spectroscopy was performed on a Perkin-Elmer Lambda 25

spectrometer.

Fluorescence measurements were taken on a Perkin-Elmer LS 55

fluorimeter. Dynamic light scattering was performed on a Malvern Zetasizer Nano-ZS.
Transmission electron microscopy (TEM) was performed using a TEM JEOL 2000FX
with samples prepared on carbon-coated copper grids purchased from Electron
Microscopy Sciences. High-resolution mass spectral (HRMS) data were obtained on a
JEOL JMS700 MStation. IR absorbance data were obtained on a Perkin-Elmer Spectrum
One FT-IR spectrometer equipped with a universal ATR sampling accessory. The HPLC
system consisted of a Waters Alliance system with a 2996 photodiode array detector and
a 2475 fluorescence detector. A size exclusion column (Shodex KW-803) eluting with
10% ethanol in PBS buffer (pH 7.4) at a flow rate of 1 mL/min was used to analyze
protein-polymer conjugate samples. A reverse phase C18 column (250 × 4.6 mm) eluting
with a gradient of 5-95% of acetonitrile in 0.05% TFA at a flow rate of 1 mL/min was
used to analyze prodrug samples. A reverse phase C18 column (250 × 4.6 mm) eluting
with 40% acetonitrile in water + 1% TFA at a flow rate of 1 mL/min was used to analyze
biological samples obtained from polyMPC-DOX animal studies. Dynamic rheological
properties of hydrogels were analyzed using a Rheometrics Mechanical Spectrometer,
performing frequency sweeps from 0-10 Hz on hydrogels in the equilibrium swollen
state. Optical microscopy was performed on a Nikon CKX41 inverted microscope and
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cell density measured by plate reader in luminescence mode (BMG Labtech FLUOstar
OPTIMA plate reader). Size exclusion FPLC was performed on a GE AKTA system
using Superose 6 10/300 columns with PBS buffer at a flow rate of 0.5 ml/min,
monitoring at 280 nm. Cation exchange FPLC was performed on a GE AKTA system
equipped with a Hitrap SP HP 5mL cation exchange column at a flow rate of 5 mL/min.
5.3 Methods


Synthesis

of

2-(2-oxo-1,3,2-dioxaphospholoyloxy)ethyl

methacrylate

(OPEMA) (10)

OPEMA was prepared according to literature procedures as described by Nakabayashi
and coworkers.1


Synthesis of 2-methacryloyloxyethyl phosphorylcholine (MPC) (11)

MPC monomer was prepared according to literature procedures, as described by
Nakabayashi and coworkers.1


Synthesis of NHS ATRP initiator (13)

NHS initiator 13 was prepared according to literature procedures.2
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Synthesis of NHS-polyMPC (14)

n

Initiator 13 (13 mg, 0.05 mmol) was dissolved in degassed DMSO (1.5 mL). To this
solution, CuBr (7 mg, 0.05) mmol) and 2,2’-bipyridine (15 mg, 0.10 mmol) was added,
followed by a solution of MPC monomer (547 mg, 1.85 mmol) in degassed methanol (0.5
mL). The reaction mixture was subjected to three freeze-pump-thaw cycles, then stirred
under inert (argon or nitrogen) atmosphere at room temperature for 12 hours. The
mixture was eluted through a short column of silica gel, and a colorless solution was
recovered. The solution was dried under vacuum, and washed with dry THF (2 mL) to
give the desired polymer (190 mg) as a white powder. 1H NMR (400 MHz, CD3OD): δ
0.81-1.33 (br), 1.81-2.22 (br), 2.87 (s), 3.25 (s), 3.69-3.81 (br), 4.04-4.45 (br) ppm;
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P

NMR (400 MHz, CD3OD): -0.3 ppm. Gel permeation chromatography, against PEO
calibration standards, eluting with 0.1 M aqueous NaNO3 containing 0.2 weight percent
NaN3: Mn 8,900, Mp 9,600, Mw 11,600, PDI 1.3.


Synthesis of 4-(2-hydroxyethoxy)benzaldehyde (15)

Sodium hydroxide (0.8 g, 20 mmol) was dissolved in 25 mL of H2O in a 2-neck round
bottom flask. The solution was stirred vigorousy. 4-Hydroxybenzaldehyde (2.44 g, 20
mmol) was added to the flask in small batches over the course of 15 minutes. 2Bromoethanol (2.49 g, 20 mmol) was added to the reaction mixture dropwise. The
114

resulting solution was heated to 98 °C for 30 hours. The reaction was cooled to 10 °C
using an ice-water bath, and the pH was adjusted to ~10 using aqueous NaOH. The
reaction mixture was then extracted with dichloromethane (4 times, 30 mL each). The
organic layers were combined and dried with MgSO4. After filtration, solvent was
removed using rotary evaporation.

The residue was purified using column

chromatography (70 % ethyl acetate/hexanes on silica gel) to afford the purified product
as a pale yellow oil (2.23 g, 67 % yield).


Synthesis of benzaldehyde ATRP initiator (16)

4-(2-hydroxyethoxy) benzaldehyde (0.96 g, 6.0 mmol) was dissolved in CH2Cl2 (13 mL)
under nitrogen atmosphere. Triethylamine (0.71 g, 7.0 mmol) was added slowly, and the
mixture was cooled to 0°C. A solution of 2-bromoisobutyryl bromide (1.3 g, 5.7 mmol)
in CH2Cl2 (4 mL) was added dropwise over the course of 10 minutes. The reaction
mixture was then stirred at room temperature for 16 hours. The reaction mixture was
filtered, washed twice with saturated aqueous NaHCO3, dried over MgSO4, filtered, then
concentrated by rotary evaporation.

The crude mixture was purified by column

chromatography over silica gel, eluting with ethyl acetate:hexane mixtures, to give the
desired product as a yellow oil (650 mg, 59 %). 1H NMR (300MHz, CDCl3): δ 9.7 (s),
7.9 (d), 7.2 (d), 4.5 (t), 4.3 (t), 1.9 (s) ppm; 13C NMR (300MHz, CDCl3): δ 30.67, 55.36,
63.79, 65.77, 114.9, 130.32, 132.05, 163.4, 171.63, 190.85 ppm; HRMS-FAB (m/z):
[M]+ calculated 315.02, found 315.0232.
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Synthesis of benzaldehyde-polyMPC (17)

n

To a stirring solution of initiator 16 (18.8 mg, 0.060 mmol) in DMSO (2 mL) under
nitrogen atmosphere was added Cu(I)Br (8.6 mg, 0.06 mmol) and bipyridine (18.7 mg,
0.120 mmol). The mixture was then subjected to two freeze-pump-thaw cycles. A
solution of MPC (479.5 mg, 1.62 mmol) in MeOH (1 mL) was then added to the mixture
using a degassed syringe. Three freeze-pump-thaw cycles were performed. The reaction
mixture was brought to room temperature, and the reaction was stirred for 18 hours. 1H
NMR spectroscopy was used to monitor monomer conversion. To remove copper and
DMSO, the mixture was purified by column chromatography over silica gel, eluting with
methanol. Solvent was removed by rotary evaporation and dried overnight under vacuum
yielding a white, crystalline solid (300 mg).

1

H NMR (300 MHz, D2O): δ 0.6-1.1 (br),

1.6-2.1 (br), 3.12 (s), 3.57 (s), 3.97 (br), 4.1-4.3 (br), 7.15 (d), 7.91 (d), 9.77 (s) ppm. The
polymer was also characterized by aqueous GPC against poly(ethylene oxide) calibration
standards, eluting with 0.1 M aqueous NaNO3 containing 0.2 weight percent NaN3: Mn =
7,000, Mp =7,500, Mw = 8,000, PDI = 1.12.


Preparation of lysozyme-polyMPC conjugate (18)

Lysozyme (1 mg, 3.3x10-5 mmol) and polymer 17 (2.5 mg, 3.5x10-4 mmol) was
dissolved in 1.5 mL of pH 6 phosphate buffer. The reaction mixture was maintained at
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ambient temperature, and gently shaken for 1 hour. NaCNBH3 (20 mg, 0.32 mmol) was
then added to the reaction. After 1 day, additional NaCNBH3 (40 mg, 0.63 mmol) was
added. The solution was incubated at room temperature with continuous, gentle shaking.
The reaction was monitored with SEC-HPLC, using a Shodex KW-804 column and a UV
detector set at 280 nm, and with SDS-PAGE.


Synthesis of pentafluorophenol ATRP initiator (20)

Pentafluorophenol (3.00 g, 16.3 mmol) was dissolved in tetrahydrofuran (30 mL,
anhydrous) in a dry 2-neck round bottom flask. Triethylamine (2.50 g, 24.5 mmol) was
added to the stirring solution slowly, and the reaction mixture was cooled to 0 °C. 2Bromoisobutyryl bromide (5.60 g, 24.5 mmol) was added to the reaction mixture
dropwise. The mixture was allowed to warm to room temperature, and stirred for 18
hours, then passed through Celite to remove TEA salt, and solvent was removed by rotary
evaporation. The residue was redissolved in dichloromethane, and washed with 1M HCl
(aq), saturated NaHCO3 (aq), and brine. The organic layers were dried over MgSO4, and
filtered, and solvent was removed. The orange liquid obtained was purified by column
chromatography over silica gel, eluting with ethyl acetate/hexanes mixture, to obtain the
pure product as a colorless liquid (4.0 g, 76 %). 1H NMR (300 MHz, CDCl3):  = 2.10
(s, 6H);

19

F NMR (282 MHz, CDCl3):  = -152.9 (2F), -157.2 (1F), -162.0 (2F);

13

C

NMR (75 MHz, CDCl3):  = 30.5, 52.9, 124.8, 136.1, 138.1, 139.4, 141.4, 142.7, 168.1.
HRMS-FAB (m/z): calculated: 331.9483, found: 331.9434.
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Synthesis of PFP-polyMPC (21)

n

In a dry 2-neck round bottom flask, initiator 20 (8.0 mg, 0.025 mmol) and MPC
monomer (500 mg, 1.7 mmol) were dissolved in 1:1 methanol/dimethylsulfoxide (3 mL),
and the stirring solution was degassed with nitrogen. Cu(I)Br (4.0 mg, 0.025 mmol) and
bipyridine (8.0 mg, 0.05 mmol) were added simultaneously as solids to the reaction flask.
The mixture was degassed for 20 minutes by bubbling with dry nitrogen gas, then sealed
and let stir at room temperature. Most reactions were run for 8-16 hours, then stopped by
exposing the reaction to air to oxidize the catalyst. Polymers were generally purified by a
short silica plug eluting with methanol, followed by precipitation into THF or acetone to
isolate a white solid (350 mg, 70 % yield). 1H NMR (300 MHz, MeOD): δ = 0.93-1.08
(3H, br), 1.85-2.1 (2H, br), 3.50 (2H, br), 4.04 (2H, br), 4.19 (2H, br), 4.29 (2H, br).
NMR (122 MHz, MeOD): δ = 0.0.
(1F), -161.6. (2F).

19

31

P

F NMR (282 MHz, CDCl3):  = -152.8 (2F), -156.8

Aqueous GPC (0.1 M NaNO3 + 0.02 wt% of NaN3): Mn, 11,700

g/mole; Mw, 15,000 g/mole; PDI, 1.3.


Synthesis of carboxylic acid 22

Bis-(MPA) (8.0 g, 60 mmol), pyridine (9 mL), and DMAP (732 mg, 6 mmol) were
suspended in dry dichloromethane (30 mL). 2-Bromoisobutyryl bromide (54 g, 29 mL)
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was added dropwise. A white solid precipitant was observed. The reaction mixture was
stirred for 12 hours, then methanol (100 mL) and glacial acetic acid (2 mL) was added.
The reaction mixture was filtered, and the solvent was collected and evaporated. The
product was purified by column chromatography using ethyl acetate/hexanes/1 % acetic
acid mixtures to afford a white solid (22 g, 38.3 %). 1H NMR (300 MHz, CDCl3):  =
1.40 (s, 3H), 1.94 (s, 12H), 4.39 (q, 4H);

13

C NMR (75 MHz, CDCl3):  = 17.7, 30.6,

46.5, 55.2, 65.9, 170.9, 178.6. FAB-MS (m/z): calculated: 429.96, found: 429.97.


Synthesis of acid chloride 23

Compound 22 (1.0 g, 2.3 mmol) was dissolved in DCM (10 mL), then cooled to 0 °C
with an ice bath. Oxalyl chloride (431 mg, 3.40 mmol) was added dropwise to the
stirring solution, then several drops of DMF were added. The mixture was warmed to
room temperature, then heated to reflux. After 3 hours, TLC indicated that the reaction
was complete, and the solvent was removed under reduced pressure.

The isolated

product was dried under vacuum, yielding 700 mg of 23 as a colorless oil (70 %).
NMR (300 MHz, CDCl3):  = 1.40 (s, 3H), 1.94 (s, 12H), 4.39 (q, 4H);
MHz, CDCl3):  = 17.7, 30.6, 46.5, 55.2, 65.9, 170.9, 174.8.
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Synthesis of compound 24

Ethylene glycol (930 mg, 15.0 mmol) was dissolved in anhydrous THF (5 mL) in a dry
round bottom flask. Triethylamine (181 mg, 1.80 mmol) was added slowly, then the
reaction flask was cooled over an ice bath. Using an addition funnel, a solution of
compound 23 (1.13 g, 2.5 mmol, dissolved in 5 mL THF) was added to the stirring
solution dropwise. The mixture was allowed to warm to room temperature, and let stir
for several hours while monitoring by TLC. TEA salt was removed by filtration over a
plug of Celite, and the product was isolated by column chromatography (silica gel,
eluting with ethyl acetate/hexanes mixture). The solvent was removed by rotovap, and
the product was dried under vacuum, yielding 24 as a colorless oil in 60 % yield (714
mg). 1H NMR (300 MHz, CDCl3):  = 1.40 (s, 3H), 1.94 (s, 12H), 3.83 (t, 2H), 4.25 (t,
2H), 4.39 (q, 4H);

13

C NMR (75 MHz, CDCl3):  = 17.9, 30.6, 46.9, 55.3, 60.8, 66.3,

67.1, 171.1, 172.6.


Synthesis of pentafluorophenyl carbonate 25

Compound 24 (2 g, 4.2 mmol) was dissolved in THF (5 mL) in a dry 100 mL round
bottom flask. Triethylamine (505 mg, 5.00 mmol) was added slowly to the stirring
solution. Bis(pentafluorophenyl) carbonate was dissolved in THF (2 mL), then added
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dropwise to the reaction mixture at 0 °C. The mixture was stirred for 16 hours, then the
solution was washed with water and saturated NaHCO3 (aq). The organic layers were
collected and dried over MgSO4, filtered and concentrated by rotary evaporation. The
residue was purified by column chromatography over silica gel, eluting with ethyl
acetate/hexanes mixtures, to afford a pale yellow oil (1.9 g, 70 %). 1H NMR (300 MHz,
CDCl3):  = 1.40 (s, 3H), 1.94 (s, 12H), 4.39 (q, 4H), 4.49 (t, 2H), 4.59 (t, 2H);

13

C

NMR (75 MHz):  = 17.7, 30.5, 46.7, 55.3, 62.4, 66.1, 67.6, 124.8, 136.1, 138.1, 139.4,
141.4, 142.7, 151.2, 170.9, 172.1; 19F NMR (282 MHz, CDCl3):  = -152.8 (2F), -156.8
(1F), -161.6. (2F). HRMS-FAB (m/z): calculated: 684.9730, found: 684.9697.


Synthesis of two-arm PFP-polyMPC (26)

n

Two-arm polyMPC was prepared using ATRP, according to the same procedure used for
polymer 21.


Synthesis of 5-(phosphorylcholine) cyclooctene (27)

PC-COE was prepared by Dr. Katrina Kratz, according to literature procedures.3
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Synthesis of 5-carboxylic acid cyclooctene (28)

PC-COE was prepared by Dr. Katrina Kratz, according to literature procedures.4


Synthesis of 5-(pentafluorophenyl ester) cyclooctene (29)

PC-COE was prepared by Dr. Katrina Kratz. Into a flame-dried two-neck flask equipped
with a N2 inlet and addition funnel, a solution of 5-carboxylic acid cycloocetene (0.032
mol, 5.0g) in THF (150 mL) was cooled to 0 C. Thionyl chloride (0.034 mol, 2.5 mL)
was added dropwise and the solution was warmed to room temperature and stirred for 1
hour. The reaction was cooled to 0 C and triethylamine (0.064 mol, 9.0 mL) was added
as a white precipitate formed. After 15 minutes, a solution of pentafluorophenol (0.035
mol, 6.5g) in THF (25mL) was added dropwise and the solution was stirred at room
temperature for 12 hours. The white solid was removed by filtration through celite and
the filtrate was concentrated. Product was purified by silica gel column chromatography
with chloroform as an eluent (Rf value: 0.8). Product was isolated in 78 % yield (0.025
mol, 6.4 g). as a yellow oil. 1H NMR (300 MHz, CDCl3):  = 5.66 (m, 2H), 3.85 (m, 1H),
2.50-2.00 (br, m, 6H), 1.80-2.0 (br m, 4H), 13C NMR (75 MHz, CDCl3): δ = 171.7, 142.6,

122

140.6, 139.9, 139.2, 138.1, 136.7, 125.3, 43.1, 31.2, 29.5, 27.8, 25.5, 23.4.

19

F NMR

(282 MHz, CDCl3):  = -152.77 (2H), -158.66 (1F), -162.77 (2F). ESI-MS: calculated
320.250, found: 321.090 (M+H+).


Synthesis of poly(PC-COE-co-PFP-COE) (30)

n

m

Poly(PC-COE-co-PFP-COE) was prepared by Dr. Katrina Kratz. PC-COE monomer 27
(3.40 mmol, 1.00 g) and PFP-COE monomer 29 (0.170 mmol, 0.042 g) were dissolved in
2 mL of dry 30 % trifluoroethanol in dichloromethane, and stirred under nitrogen. In a
separate vial, the pyridine substituted ruthenium benzylidene methathesis catalyst 5 (0.024
mmol, 30 mg) was dissolved in dichloromethane (0.1 mL). The catalyst solution was
injected rapidly into the monomer solution, and the mixture was stirred for 30 min. Ethyl
vinyl ether (0.5 mL) was added to terminate the polymerization, and the solution was
concentrated under vacuum. The crude product was dissolved in methanol (~0.1 mL) and
poured into an excess of acetone. The resulting polymer was filtered, dried under
vacuum, purified by dialysis in water (2,000 g/mol MWCO) and then lyophilized to
afford 70 % of a white solid. 1H-NMR (300 MHz, 25 % MeOD in CDCl3):  = 5.17 (m,
2H), 4.0 (m, 3H), 3.48 (t, 2H), 3.0 (s, 9H), 2.60 (br, 1H) 1.80-2.0 (br m, 4H), 1.5-1.7 (br
m, 2H), 1.2-1.4 ( br m, 4H).

13

C-NMR (75 MHz, 25% MeOD in CDCl3):  = 171.7,

142.6, 140.6, 139.9, 139.2, 138.1, 136.7, 135.0, 134.0, 70.0, 65.0, 58.2, 47.2, 43.1, 34.6,
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34.0, 24.8, 24.1, 21,8.

31

P-NMR (122 MHz, 25% MeOD in CDCl3):  0.0.

19

F-NMR

(282 MHz, 25% MeOD in CDCl3):  = -152.77 (2H), -158.66 (1F), -162.77 (2F).


Preparation of Lysozyme-polyMPC Conjugates (32-34)

In general, lysozyme was dissolved in pH 9 borate buffer at a concentration of 10
mg/mL. The buffered protein solution was added to a vial containing an excess of the
phosphorylcholine polymer (20 molar equivalents). The reaction mixture was gently
shaken at room temperature, and conjugation progress was monitored by size exclusion
high performance liquid chromatography (SEC-HPLC) eluting with 10 % ethanol/PBS at
1.0 mL/min. The conjugates were purified using fast protein liquid chromatography
(FPLC) eluting with PBS at 0.5 mL/min, or dialysis (MWCO 20,000).


Preparation of AF647-labeled lysozyme-polyMPC conjugate (35)

Lysozyme and lysozyme-polyMPC conjugates were labelled with Alexa Fluor 647
succinimidyl ester purchased from Invitrogen, according to the manufacturer's
instructions. The labeled lysozyme and conjugates were purified by passage through a
bio-gel P4 gel column with PBS as eluent. Fractions containing the labeled products were
collected and combined. The labeled lysozyme and conjugates were concentrated with
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Centricon YM-3 by filtering off the PBS. After measuring the UV/Vis absorbance at 280
and 650 nm, the concentration and degree of labeling were calculated based on the
manufacturer’s protocol. The purified conjugates were also characterized by fluorescence
spectroscopy, and HPLC with a fluorescence detector..


Synthesis of 2-hydroxyethyl 2-bromoisobutyrate (38)

To a solution of ethylene glycol (2 g, 0.032 mol) in 10 mL of anhydrous tetrahydrofuran
(THF), triethylamine (1.95 g, 0.019 mol) was added. The solution was cooled on ice
while stirring. Using an addition funnel, 2-bromoisobutyryl bromide (3.6 g, 0.16 mol) in
5 mL THF was added dropwise to the solution. Gradually allowed to warm to room
temperature, and continued to stir for 18 hours. The TEA salt was subsequently filtered
off, and the remaining solution was concentrated by rotary evaporation. The residue was
the purified by column chromatography on silica gel, eluting with 20:80 ethyl
acetate/hexanes. The product was obtained as a colorless liquid (2 g, 59 %).

1

H NMR

(300 MHz, CDCl3): δ = 1.95 (s, 6H), 3.87 (t, 2H), 4.41 (t, 2H). HRMS-FAB (m/z):
[M+H]+ calculated for C6H11BrO3: 210.99, found: 210.9970.


Synthesis of t-boc-aminooxy ATRP initiator (39)

Compound 38 (1 g, 4.76 mmol) and t-boc aminooxy acetic (909 mg, 4.76 mmol) were
dissolved in 50 mL of anhydrous dichloromethane. The flask was cooled to 0 °C on ice,
and EDC and DMAP were added simultaneously to the reaction. Gradually let warm to
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room temperature, and continued stirring for 18 hours. The solvent was then removed by
rotary evaporation, and the residue was purified by column chromatography on silica gel,
eluting with 80:20 ethyl acetate/hexanes, to afford to product as a colorless oil in (1.7 g,
94 %). 1H NMR (300 MHz, CDCl3): δ = 1.46 (s, 9H), 1.93 (s, 6H), 4.4 - 4.7 (m, 6H),
7.78 (s, 1H). 13C NMR (75 MHz, CDCl3): δ = 28.16, 30.60, 55.28, 62.35, 63.21, 72.50,
82.14, 156.24, 169.39, 171.52. FAB-MS (m/z): [M+H] calculated for C13H22BrNO7:
384.06, found: 384.07.


Synthesis of aminooxy-polyMPC (40)

(

)

n

MPC monomer (2 g, 6.75 mmol) and initiator 39 (75 mg, 0.198 mmol) were added to a
round bottom flask and dissolved in 3 mL of anhydrous methanol and 5 mL of anhydrous
DMSO with stirring. The solution was purged with nitrogen for 10 minutes. Cu(I)Br (28
mg, 0.198 mmol) and bipyridine (62 mg, 0.397 mmol) were added as solids to the
reaction mixture under a stream of nitrogen. The mixture was degassed with nitrogen for
10 minutes, then let stir overnight at room temperature.

The polymerization was

monitored using 1H NMR, stopped by exposure to air, oxidizing the Cu catalyst. The
mixture was precipitated into THF, redissolved, and passed over a plug of silica eluting
with methanol. Solvent was removed to give the polymer product as a white solid (1.5 g,
72 %).

Polymers were characterized by 1H NMR and aqueous GPC for relative

molecular weight determination.

PolyMPC (1g) was dissolved in 10 mL of 10 %

methanol in trifluoroacetic acid solution and stirred at room temperature to achieve chainend deprotection. After 3 hours, solvent was removed by rotary evaporation. The
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polymer residue was dissolved in water, and purified by dialysis (MWCO 1000).
Lyophilization resulted in the desired polymers as white solids. GPC analysis confirmed
that no polymer degradation was caused by the harsh acid treatment, and 1H NMR was
used to confirm the disappearance of the t-boc protecting group.


Synthesis of 4-hydroxybenzaldoxime-polyMPC (41)

n

PolyMPC 40 (100 mg, 0.02 mmol) was added to a small reaction vessel, and dissolved in
300 uL of pH 9 borate buffer. 4-hydroxybenzaldehyde (3 mg, 0.024 mmol) was added,
and the reaction was vortexed to dissolve, then gently shaken for 18 hours at room
temperature. A 20 uL aliquot was removed and diluted to 1mL and injected onto aqueous
GPC, monitoring with a UV detector set to 280 nm. Comparing the signal intensity
obtained from polymer 40 and conjugate 41 indicated that oxime formation occurred,
linking the UV-active benzaldehyde moiety to the polymer chain.


Synthesis of pentafluorophenyl levulinate (43)

Levulinic acid (1 g, 0.0085 mol) and pentafluorophenol (1.4 g, 0.0075 mol) were added
to a 100 mL round bottom flask, and dissolved in 30 mL of anhydrous dichloromethane.
The reaction flask was cooled on ice, then EDC (1.7 g, 0.009 mol) and DMAP (92 mg,
0.00075 mol) were added together as solids. The reaction was allowed to gradually warm
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to room temperature, and continued stirring for 18 hours. The desired product was
purified by column chromatography on silica gel, eluting with 1-5 % methanol in DCM,
to yield 43 as a white solid (2 g, 95 %).
2.88 - 2.95 (m, 4H).

19

1

H NMR (300 MHz, CDCl3): δ = 2.22 (s, 3H),

F NMR (282 MHz, CDCl3): δ = -152.5 (2F), -157.9 (1F), -162.3

(2F).


Synthesis of lysozyme-levinate (44)

Lysozyme (250 mg, 0.0174 mmol) was dissolved in 10 mL of pH 9 sodium borate buffer.
In a separate vial, 43 (50 mg, 0.174 mmol) was dissolved in 1 mL of DMSO, then added
dropwise to the protein solution.

After 2 hours, cation exchange FPLC indicated

complete conversion from native lysozyme. The reaction mixture was transferred to a
dialysis membrane and dialyzed against pure water. Lyophilization afforded a white
solid. ESI-MS revealed a mixture of products.


Synthesis of lysozyme-polyMPC conjugate (45)

A 10 mg/mL solution of lysozyme in the desired buffer was prepared, and to it, 20 molar
equivalents of aminooxy polyMPC was added.

The reactions were kept at room

temperature and gently agitated, and 50 uL aliquots were removed at predetermined time
points and diluted to a final volume of 500 uL. 50uL was injected to SEC-HPLC to
monitor conversion to conjugate.
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Synthesis of TMS-propargyl methacrylate (47)

The TMS protected alkyne monomer was synthesized according to the literature.6 3(Trimethylsilyl)propargyl alcohol (2 g, 15.6 mmol) and triethylamine (2 g, 20.3 mmol) in
20 mL of dry ethyl ether was cooled to -20 °C. A solution of methacryloyl chloride (2 g,
18.7 mmol) in 10 mL of dry ethyl ether was added dropwise over 30 min. The reaction
mixture was stirred for 30 min at -20 °C, then overnight at room temperature. The
precipitation was removed by filtration and the solvent was removed by rotary
evaporation. The crude product was further purified on silica column chromatography
eluted with hexane-ethyl ether (100:1) to give the pure TMS-PgMA monomer as clear oil
(4.0 g, 58 % yield). IR: (cm-1) 2961 (C-H), 1723 (C=O), 1638 (C=C). 1H NMR (CDCl3,
300 MHz): δ 6.16 (m, 1H), 5.61 (m, 1H), 4.75 (s, 2H), 1.95 (m, 3H), 0.18 (s, 9H).

13

C

NMR (CDCl3, 75 MHz): δ 166.6, 135.7, 126.4, 99.1, 91.9, 53.0, 18.3, 0.3. HRMS-FAB
(m/z): [M]+ calculated for C10H16O2Si: 196.0920, found: 196.0891.


Synthesis of CPT-azides (48)

EDC/DMAP
DCM

NaN3
DMSO

Several linkers were prepared for CPT. for example, an alkyl linker was synthesized
according to the literature.7 6-bromohexanoic acid (5 g, 25.6 mmol) was reacted with
sodium azide (8.4 g, 129 mmol) in 50 mL of DMSO at room temperature to generate 6azidohexanoic acid, which then was reacted with CPT using EDC/DMAP as coupling
agents in DCM to obtain compound 48. IR: (cm-1) 2094 (N=N=N). 1H NMR (CDCl3, 300
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MHz): δ 8.43 (s, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.87 (t, J = 7.0
Hz, 1H), 7.70 (t, J = 7.1 Hz, 1H), 7.23 (s, 1H), 5.71 (d, J = 17.6 Hz, 1H), 5.43 (d, J = 17.6
Hz, 1H), 5.31 (s, 2H), 3.25 (t, J = 6.8 Hz, 2H), 2.45-2.63 (m, 2H), 2.11-2.37 (m, 2H),
1.71 (qp, J = 7.6 Hz, 2H), 1.63 (m, 2H), 1.42 (m, 2H), 1.00 (t, J = 7.3 Hz, 3H).
Jones Reagent
NaN3
Water
EDC/DMAP
DCM

Alternatively, chromium trioxide (25 g, 164 mmol) was dissolved into 300 mL of 1.5 M
H2SO4 and the solution was cooled to 0 °C. 2-[2-(2-chloroethoxy)ethoxy]ethanol (8.3 g,
49 mmol) in 150 mL acetone was added into the Jones reagent dropwise and the reaction
mixture was stirred at room temperature for 6 h. The acetone was removed by
evaporation under vacuum and the aqueous phase was extracted with DCM (3 × 100
mL). After the combined organic phase was dried over MgSO4, 2-[2-(2chloroethoxy)ethoxy]acetic acid (6.3 g, 70 % yield) was obtained by removing the
solvent by rotary evaporation. IR: (cm-1) 1734 (C=O). 1H NMR (CDCl3, 300 MHz): δ
10.49 (b, 1H), 4.23 (s, 2H), 3.80 (t, J = 5.8 Hz, 4H), 3.74 (t, J = 5.7 Hz, 2H), 3.66 (t, J =
5.8 Hz, 2H). 13C NMR (CDCl3, 75 MHz): δ 174.4, 71.4, 71.1, 70.4, 68.5, 42.6. 2-[2-(2chloroethoxy)ethoxy]acetic acid (6.3 g, 34.4 mmol) and NaN3 (9 g, 138 mmol) were
dissolved in 20 mL of water. The reaction mixture was refluxed at 80 °C for 48 h. After
cooling to room temperature, the reaction mixture was acidified with HCl solution and
extracted with DCM (4 × 50 mL). The combined organic phase was dried over MgSO4
and then MgSO4 was removed by filtration. Solvent was removed under reduced pressure
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to obtain the linker as clear oil (5.0 g, 77 % yield). IR: (cm-1) 2097 (N=N=N). 1H NMR
(CDCl3, 300 MHz): δ 10.80 (b, 1H), 4.22 (s, 2H), 3.79 (t, J = 5.7 Hz, 2H), 3.69-3.74 (m,
4H), 3.43 (t, J = 5.3 Hz, 2H). 13C NMR (CDCl3, 75 MHz): δ 174.7, 71.2, 70.5, 70.1, 68.4,
50.6. HRMS-FAB (m/z): [M+H]+ calculated for C6H12O4N3: 190.0828, found: 190.0816.
2-[2-(2-azidoethoxy)ethoxy]acetic acid (327 mg, 1.72 mmol) and EDC hydrochloride
(330 mg, 1.72 mmol) were dissolved in 20 mL DCM at 0 °C. CPT (300 mg, 0.86 mmol)
and DMAP (210 mg, 1.72 mmol) were added. The reaction was stirred at room
temperature till the suspension turned clear. After washing with 1 N HCl (50 mL × 3), 1
% NaHCO3 (50 mL × 3), and brine (50 mL × 1), the organic phase was dried over
MgSO4. After filtration, the solvent was removed by evaporation to gave a yellow solid,
which is recrystallized from MeOH/CH2Cl2 (95:5) to give CPT azide 48 (389 mg, 87 %
yield) as light yellow solid. IR: (cm-1) 2104 (N=N=N). 1H NMR (CDCl3, 300 MHz): δ
8.43 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.87 (t, J = 7.5 Hz, 1H),
7.70 (t, J = 7.5 Hz, 1H), 7.23 (s, 1H), 5.73 (d, J = 17.4 Hz, 1H), 5.44 (d, J = 17.4 Hz, 1H),
5.31 (s, 2H), 4.39 (d, J = 5.0 Hz, 2H), 3.77 (t, J = 5.5 Hz, 2H), 3.66-3.70 (m, 4H), 3.40 (t,
J = 5.1 Hz, 2H), 2.13-2.39 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3, 75 MHz):
δ 169.7, 167.3, 157.3, 152.2, 148.9, 146.4, 145.4, 131.2, 130.7, 129.6, 128.4, 128.2,
128.2, 128.1, 120.3, 95.9, 76.4, 71.1, 70.6, 70.0, 68.2, 67.2, 50.6, 50.0, 31.8, 7.6. HRMSFAB (m/z): [M+H]+ calculated for C26H26O7N5: 520.1832, found: 520.1821.
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Synthesis of poly(MPC-g-CPT) (49)

CPT azide compound was charged into a 10 mL two-neck round-bottom flask and three
cycles of vacuum-nitrogen were employed. Nitrogen gas bubbled DMSO (2 mL) was
injected with a syringe. After the CPT azide was completely dissolved, a solution of ethyl
2-bromoisobutyrate (11.7 mg. 0.06 mmol), MPC and alkyne monomer in 0.7 mL
methanol was injected. CuBr (17 mg, 0.12 mmol) and bipyridine (37.4 mg, 0.24 mmol)
were added quickly under nitrogen atmosphere. The reaction mixture was then subjected
to four freeze-pump-thaw cycles. The reaction mixture was stirred at room temperature
for 20 h and the polymerization conversion was monitored by

1

H NMR. The

polymerization was stopped by precipitating the reaction mixture into THF (100 mL) and
the crude product was isolated by filtration. The crude product was further purified on
silica column with MeOH/CH2Cl2 (95:5) as eluent to give the polyMPC-g-CPT
copolymers as light yellow solid. The polymers were characterized using NMR and
aqueous GPC.


Synthesis of HEMA-LA monomer (51)

Lipoic acid (4.00 g, 19.4 mmol) and 2-hydroxyethyl methacrylate (2.50 g, 19.4 mmol)
were dissolved in 60 mL of anhydrous CH2Cl2 in a dry roundbottom flask. The stirring
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solution was cooled to 0 °C, and EDC (7.40 g, 38.8 mmol) and DMAP (2.40 g, 19.4
mmol) were added as solids. The reaction mixture was allowed to warm to room
temperature, and stirred for 18 hours. The mixture was diluted with dichloromethane,
and washed with 1 M HCl(aq), saturated NaHCO3(aq), and brine. The organic layer was
dried over MgSO4, filtered, and concentrated by rotary evaporation, to give monomer 51
as a yellow oil (4.9 g, 80 % yield). 1H NMR (300 MHz, CDCl3):  = 6.06 (s, 1H), 5.36
(s, 1H), 4.26 (s, 4H), 3.5 (m, 1 H), 3.11 (m, 2H), 2.40 (m, 1H), 2.3 (t, 2H), 1.87 (s, 3H),
1.35-1.70 (m, 8H) ppm.

13

C NMR (75 MHz, CDCl3):  = 18.31, 24.60, 28.70, 33.87,

34.58, 38.49, 40.21, 56.29, 61.99, 62.43, 126.10, 135.89, 167.08, 173.22 ppm.


Synthesis of poly(MPC-b-DHLA) copolymer (55)

m

n

MPC (1.00 g, 3.37 mmol), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (19 mg,
0.067 mmol), and 4,4'-azobis(4-cyanovaleric acid) (ACVA) (4.0 mg, 0.014 mmol) were
added to a dry round bottom flask. Methanol (3 mL) and dimethylsulfoxide (DMSO) (2
mL) were added and the solution was degassed for 20 minutes by bubbling with dry
nitrogen gas. The reaction mixture was placed in a preheated oil bath at 70 °C and stirred
for 6 hours. In a separate vial, HEMA-LA 51 (212 mg, 0.67 mmol) was dissolved in
DMSO (1 mL) and degassed for 30 minutes. The solution of 1 was added rapidly to the
reaction flask by syringe, and stirring was continued for 12 hours. Propagation was
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terminated by placing the solution in liquid nitrogen, then allowing the mixture to warm
while open to air. The solution was then passed through a short plug of silica gel, eluting
with methanol, then precipitated into THF to afford polymer 54 as a pink solid. This
solid was dissolved in 20 mL of degassed water, and stirred at 0 ºC. Sodium borohydride
(102 mg, 2.68 mmol) was added under a stream of nitrogen. The reaction mixture was
stirred at 0 °C for 1 hour, then at 25 °C for 1 hour. HClconc was added to adjust the pH to
~3, and the polymer was purified by dialysis (MWCO 1,000) against methanol and water
at 4 °C. Lyophilization afforded the desired block copolymer 55 in 80 % yield as white
solids. 1H NMR (300 MHz, MeOD/CDCl3):  = 4.32 (2H, br), 4.22 (2H, br), 4.07 (2H,
br), 3.75 (2H, br), 2.95 (2H, br), 2.71 (2H, br), 2.45 (2H, br), 1.37-2.28 (H, br), 0.52, 1.23
(3H, br).

13

C NMR (175 MHz, MeOD/CDCl3):  = 16.91, 18.59, 21.81, 24.45, 26.31,

33.78, 38.43, 39.01, 42.70, 44.70, 45.10, 53.76, 59.09, 64.70, 66.09, 173.44, 176.79,
177.60, 177.87. GPC (TFE + 0.2 M Na trifluoroacetate, 1 eq DTT, PMMA standards):
Mn, 26,900; PDI 1.24.


Synthesis of 3-(pyridyl disulfide) propionic acid linker (56)

Comound 56 was synthesized according to literature procedure.8 2,2'-Dithiodipyridine
(500 mg, 2.27 mmol) was dissolved in ethyl acetate (2.5 mL) with stirring in a
roundbottom flask. Separately, 3-mercaptopropionic acid (160 mg, 1.51 mmol) was
dissolved in ethyl acetate (1.5 mL), and added dropwise to the stirring solution, which
gradually became yellow. One drop of boron trifluoride diethyl etherate was added.
After 7 hours, the reaction mixture was concentrated by rotary evaporation and purified
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by column chromatography on silica gel, eluting with methanol/dichloromethane
mixtures to give the desired product as a yellow oil in 95 % yield (307 mg).

1

H NMR

(300 MHz, CDCl3):  = 12.8 (s, 1H), 8.4 (br, 1H), 7.6 (br, 2H), 7.1 (br, 1H), 3.04 (tr, 2H),
2.8 (tr, 2H).

13

C NMR (75 MHz, CDCl3):  = 33.71, 34.01, 114.32, 121.19, 134.00,

138.06, 149.93, 176.16.


Synthesis of CPT-pyridyl disulfide (57)

Camptothecin-pyridyl disulfide was prepared according to literature procedures.9
Compound 56 (232 mg, 1.07 mmol) was dissolved in anhydrous dichloromethane (30
mL) in a roundbottom flask. Camptothecin (250 mg, 0.718 mmol) was added to form a
pale yellow suspension.

EDC (276 mg, 1.44 mmol) and DMAP (175 mg, 1.44 mmol)

were added. The mixture was stirred for 24 hours, then diluted with dichloromethane, and
washed with 1M HCl (aq), brine, and water. The organic layer was dried over MgSO4,
filtered, and concentrated by rotary evaporation. The residue was further purified by
column chromatography on silica gel, eluting with methanol/dichloromethane to give the
desired product as a yellow solid in 50 % yield (195 mg). 1H NMR (300 MHz, DMSO):
 = 8.71 (s, 1H), 8.48 (d, 1H), 8.14 (m, 2H), 7.62-7.83 (m, 3H), 7.36 (d, 1H), 7.11-7.2 (m,
2H), 5.51 (s, 2H), 5.31 (s, 2H), 3.34 (m, 2H), 2.96 (m, 2H), 2.15 (m, 2H), 0.90 (tr, 3H).
13

C NMR (175 MHz, DMSO):  = 171.01, 167.57, 157.61, 156.96, 153.82, 150.01,

148.33, 146.37, 145.73, 137.10, 132.00, 130.90, 130.25, 129.29, 129.00, 128.42, 128.14,
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122.75, 120.40, 119.28, 95.66, 76.56, 66.72, 50.66, 34.25, 30.65, 29.36, 7.99. HRMSFAB [M+H]: calculated: 546.115, found: 546.113 g/mole.


Synthesis of polyMPC-CPT loaded micelles (58)

n

m

Polymer 55 (50 mg, 0.064 mmol DHLA) and camptothecin-pyridyl disulfide (16 mg,
0.029 mmol) were dissolved in methanol/DMSO (5 mL). The solution was stirred
vigorously at 37 °C for 72 hours, then dialyzed against methanol to remove unconjugated
camptothecin.

The polymer solution was dialyzed against water to induce micelle

formation, and bubbled with air to promote disulfide formation from residual thiols.
Micelle solutions were passed through 0.45 μm filters to remove any free CPT, and
lyophilized to produce off-white solids which were re-dissolved in water or methanol for
characterization.

CPT loading, as a weight percent, was determined using UV/Vis

spectroscopy, comparing to a sample of known concentration.
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Synthesis of 2-ethoxy-2-oxoethyl methacrylate (59)

Monomer 59 was prepared by Dr. Xiangji Chen. Sodium methacrylate (9.7 g, 90 mmol)
and 10.02 g of ethyl bromoacetate (60 mmol) were added into 55 mL of dry acetonitrile.
To the suspension, 3.5 g of tetrabutylammonium bromide (TBAB) was added. The
reaction mixture was heated to reflux overnight. The salt was removed by filtration and
solvent was removed by evaporation under reduced pressure. The residue was redissolved
in ethyl acetate and washed four times with water. The organic phase was dried over
MgSO4 and removal of the solvent gave the desired monomer as a pale yellow oil (9.8 g,
95 %). 1H NMR (CDCl3, 300 MHz): δ 6.21 (s, 1H), 5.64 (m, 1H), 4.66 (s, 2H), 4.22 (q,
2H), 1.97 (s, 3H), 1.27 (t, 3H). 13C NMR (CDCl3, 75 MHz): δ 167.9, 166.7, 135.4, 126.8,
61.4, 60.9, 18.2, 14.1.


Synthesis of polyMPC-co-EtOEMA (60)

n

m

Initiator EBiB (5.9 mg, 0.03 mmol), MPC and EtOEMA were charged to a 10 mL twoneck round-bottom flask and three cycles of vacuum-nitrogen were employed. Nitrogen
gas-bubbled DMSO and MeOH were injected with a degassed syringe. The reaction
mixture was bubbled with nitrogen gas for 20 min. Cu(I)Br (8.6 mg, 0.06 mmol) and
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bipyridine (18.7 mg, 0.12 mmol) were added as solids quickly under nitrogen
atmosphere. The reaction mixture was then bubbled with nitrogen gas for another 20 min
and left under nitrogen atmosphere. The reaction mixture was stirred at room temperature
and the polymerization conversion was monitored by 1H NMR. The polymerization was
stopped by exposing to air. The crude product was purified by silica column eluting with
methanol to give the poly(MPC-co-EtOEMA) random copolymer as a white solid. The
monomer ratio in the copolymer was characterized by 1H NMR spectroscopy, comparing
the peak integration at 3.58 ppm (-CH2-N in MPC) to peak integration at 1.27 ppm ((CH3) in EtOEMA).


Synthesis of polyMPC-co-Hydrazine (61)

n

m

Poly(MPC-co-EtOEMA) 60 was dissolved in methanol at a concentration of 100-200 mg
/mL. Hydrazine monohydrate was added to the polymer solution to a final concentration
of 25 %. The reaction mixture was stirred at room temperature, monitoring by 1H NMR
spectroscopy. Upon completion, the reaction mixture was diluted with water and purified
by dialysis against water with MWCO 1000 membrane for 2 days and filtered through a
0.45 µm filter. The copolymer was obtained as a white powder after lyophilization. The
average yield was over 80 % and the loading of the hydrazine group was calculated by
comparing the peak integration at 3.58 ppm (–CH2-N in MPC) to peak integration at 4.64
ppm (-CH2-CONHNH2) on 1H NMR spectrum. 1H NMR (MeOD, 300 MHz): δ = 0.9-1.2
138

(br, 3H), 1.8-2.3 (br, 2H), 3.3 (s, 9H), 3.75 (br, 2H), 4.16 (br, 2H), 4.3 (br, 2H), 4.38 (br,
2H), 4.64 (br, 2H).

13

C NMR (MeOD, 100 MHz):  = 16.8, 18.5, 44.7, 45.0, 53.4, 59.3,

62.2, 62.9, 64.8, 66.1, 167.1, 176.9, 178.1. GPC (0.1 M NaNO3 + 0.02 wt % NaN3, PEO
standards): Mn, 25,000; PDI 1.4.


Synthesis of polyMPC-DOX (62)
*

*

n

m

• HCl

MPC copolymer 61 (200 mg, 0.165 mmol -NHNH2) and DOX•HCl (58 mg, 0.1 mmol)
were dissolved in anhydrous methanol (5 mL). To this solution, 60 μL of acetic acid and
200 mg of anhydrous magnesium sulfate were added. The reaction mixture was stirred in
the dark at room temperature for 2 days. The resulting conjugate was purified first by
passage over a Sephadex LH-20 column eluting with methanol. Fractions containing
polymer-DOX conjugate were concentrated by rotary evaporation, redissolved in water,
and further purified by Sephadex G-25 column eluting with pure water. PolyMPC-DOX
conjugate 62 was obtained as a dark red powder after lyophilization (230 mg, 88 %).


Synthesis of GRGDS-methacrylamide (63)

5
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Standard solid phase peptide synthesis procedures were used, starting from a 2chlorotrityl chloride resin containing 1.6 mmol/g active sites. Resin (3.0 g, 4.8 mmol)
was added to the reaction vessel, and 30 mL of anhydrous dichloromethane was added.
The suspension was agitated with dry nitrogen pressure for 30 minutes to swell the resin.
Separately, Fmoc-Ser(But)-OH (3.7 g, 9.6 mmol) was dissolved in 30 mL of anhydrous
dichloromethance.

DIPEA (2.47 g, 19.2 mmol) was injected to the serine solution

immediately prior to addition to the reaction vessel. The peptide-resin mixture was
agitated with nitrogen pressure for one hour at room temperature. The reaction mixture
was filtered. CH2Cl2:MeOH:DIPEA (80:15:5) (30 mL) was added, and agitated with
nitrogen pressure for 10 minutes, to block any unreacted active sites. The solution was
filtered, and 30 mL of fresh CH2Cl2/MeOH/DIPEA solution was added and agitated for
10 minutes. The resin was washed with 30 mL DMF (3 x 1 minute each). The amino
acid was deprotected using a 25 % piperidine solution in DMF, agitating for three
minutes, then exchanging for fresh solution and agitating for 20 minutes. The resin was
washed with DMF (6x), CH2Cl2 (3x), isopropanol (3x), hexanes (6x), and once with
dichloromethane, then dried under vacuum overnight. Serine loading was calculated to
be 1.36 mmol/g. Aspartic acid (6.7 g, 16.32 mmol), HBTU (5.3 g, 16.3 mmol), and
HOBt (2.20 g, 16.3 mmol) were dissolved in 40 mL anhydrous DMF. DIPEA (4.20 g,
32.6 mmol) was added, and the solution was quickly transferred to the reaction vessel
containing the serine-loaded resin and agitated with nitrogen pressure for 1 hour. The
solution was filtered, and washed with DMF (3x), then deprotected with 25 % piperidine
in DMF. After filtering, the resin was washed with DMF (6x). This procedure was
repeated for the additions of glycine, arginine, glycine, N-Fmoc-amidocaproic acid, and
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methacrylic acid. After the addition of methacrylic acid, the resin was washed with
dichloromethane (6x), and then agitated for 1 hour with a 95:2.5:2.5 trifluoroacetic
acid:water:triisopropylsilane solution to cleave the peptide from the resin. The solution
was filtered into a dry round bottom flask; the cleavage procedure was then repeated
twice.

The peptide solution was concentrated to a minimal volume using rotary

evaporation and precipitated into 1 L diethyl ether.

The GRGDS-methacrylamide

monomer 63 was recovered as a white solid by filtration and dried under vacuum (1.9 g,
1

45 %).

H NMR (300 MHz, DMSO):  = 7.9-8.5 (br, 8H), 5.61 (s, 1H), 5.28 (s, 1H),

4.55-4.75 (br, 3H), 4.2-4.4 (br, 2H), 3.6-3.85 (br, 6H), 3.15 (br, 4H), 3.0 (br, 1H), 2.85
(br, 1H), 2.7 (br, 1H), 2.55 (br, 2H), 2.12 (tr, 2H), 1.84 (s, 3H), 1.5 (br, 8H), 1.25 (br,
2H).

13

C NMR (75 MHz, DMSO):  = 173.19, 172.27, 172.15, 171.97, 171.39, 171.11,

170.23, 169.78, 169.10, 167.85, 157.12, 140.53, 119.21, 67.08, 65.38, 55.28, 52.65,
51.06, 49.65, 42.42, 36.72, 35.53, 29.48, 29.30, 26.56, 25.38, 19.13. ESI-MS [M+H]:
calculated, 672.3; found, 672.4.


Synthesis of polyMPC-co-DHLA-co-GRGDS (64)

n

MPC

(1.0

g,

3.4

m

mmol),

p

5

HEMA-LA

(218

mg,

0.69

mmol),

and

2,2'-

azobisisobutyrylnitrile (AIBN) (8 mg, 0.05 mmol) were added to a dry round bottom
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flask. A 1:1 mixture of MeOH and DMSO (6 mL total volume) was added and the
solution was purged with dry nitrogen gas.

The reaction mixture was placed in a

preheated oil bath at 70 °C and stirred for 4 hours. Propagation was terminated by
placing the solution in liquid nitrogen, then allowing the mixture to warm while open to
air. The solution was precipitated into THF to afford the polymer product as an off-white
solid. This solid was dissolved in 20 mL of degassed water, and stirred at 0 ºC. Sodium
borohydride (104 mg, 2.74 mmol) was added under a stream of nitrogen. The reaction
mixture was stirred at 0 ºC for 1 hour, then at 25 ºC for 1 hour. HCl (conc) was added to
adjust the pH to ~3, and the polymer was purified by dialysis (MWCO 1,000) against
methanol and water at 4 °C. Lyophilization afforded the desired copolymer 64 as a white
solid. 1H NMR (300 MHz, MeOD): = 4.4 (br, 2H), 4.3 (br, 2H), 4.1 (br, 2H), 3.75 (br,
2H), 3.0 (br, 2H), 2.75 (br, 2H), 2.5 (br, 2H), 1.5-2.1 (br, 5H), 0.8-1.1 (br, 3H).

13

C NMR

(100 MHz, MeOD/CDCl3):  = 177.5, 66.1, 62.9, 59.3, 53.8, 45.0, 44.7, 42.7, 39.0, 38.4,
33.6, 26.4, 24.4, 21.8, 18.6, 16.7. Aqueous GPC (0.2 M NaNO3 + 0.01 % NaN3; PEO
standards): Mn, 64,200 g/mole; PDI, 4.4. This general procedure was used for all of the
GRGDS-containing polymers, adding the desired amount of oligopeptide comonomer at
the outset of the polymerization.


Preparation of polyMPC hydrogel (65)
n

m

p
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Stock solutions of poly(MPC-co-DHLA) (with and without the GRGDS peptide) were
prepared at a concentration of 100 mg/mL in pH 9 sodium borate buffer. Separately, a
stock solution of PEG2000DA cross-linker was prepared at a concentration of 180 mg/mL
in sodium borate buffer.

The poly(MPC-co-DHLA) and PEGDA solutions were

combined to give a [SH]:[acrylate] ratio of 1:1, then heated to 37 °C for 20 minutes. The
resulting hydrogels were swelled in pure water or PBS, which was changed several times
to remove any uncross-linked material.

The equilibrium water content (EWC) was

determined by comparing the weight of the gel after swelling in water for 3 days to the
weight of the dry gel. Equation 1 was used to determine EWC (as a percent):
-

(1)

where Ws and Wd are the weights of the swollen and dried gels, respectively. Excess
water was removed from the hydrogel by gently wicking with filter paper. Dynamic
mechanical analysis was used to characterized the physical properties of the hydrogels.
PolyMPC-co-DHLA hydrogels were prepared with PEG700DA as the cross-linker, with a
polyMPC-co-DHLA concentration of 50 mg/mL in pH 9 borate buffer. The hydrogel
samples were swelled to equilibrium for 48 hours.

Frequency response tests were

conducted at room temperature, from 0 - 10 Hz, and the storage (G') and loss (G") moduli
were recorded.


Determination of lysozyme activity

The activity of lysozyme, and lysozyme – polymer conjugates, was measured using the
EnzChek® Lysozyme Assay kit purchased from Invitrogen. The samples were diluted in
the reaction buffer provided, generating samples of protein equivalent concentrations, and
incubated at 37 °C for 1 hour with the substrate Micrococcus lysodeikticus fluorescently
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labeled with fluorescein.

The fluorescence intensity of the digestion product was

measured using excitation/emission wavelengths of 485/535 nm, respectively.

The

activities of the conjugates were determined from the relative fluorescence intensities.


Pharmacokinetics of PC-polymer protein conjugates

All procedures were performed in accordance with NIH guidelines for the ethical
treatment of animals, and were approved by the Baystate Medical Center Institutional
Animal Care and Use Committee. The AF647-labeled lysozyme and linear polyMPC
conjugate were injected into the lateral tail vein of C57bl/6 mice (~20 g) intravenously, at
a dose of 1.5 mg/kg (AF647 concentration) with 6 mice in each group. At specified time
points, 40 uL of blood was withdrawn from the tail vein, followed by centrifugation at
1500 g for 15 minutes at 4 °C to sediment the blood cells. The samples were stored at 80 °C until analysis. 10 µL of the plasma sample was diluted with 20 µL of PBS in a
HPLC vial, and 25 µL of each diluted sample was injected into the HPLC and analyzed
using a fluorescence detector, with excitation at 650 nm and emission at 670 nm. The
area under the curve (AUC) for the conjugate was recorded and converted to
concentration of AF dye using a calibration curve constructed from samples of known
concentrations.


Drug release from polyMPC-g-CPT conjugates

The CPT containing polymers were dissolved into different media at concentration of 3
mg/mL. The mixtures were incubated at 37˚C and aliquots (100 µL) were taken out at
different time points. Twenty µL of the sample from PBS and cell culture media were
analyzed on SEC-HPLC. The sample taken from mouse serum and human plasma were
mixed with 200 uL of PBS and filtered through 0.45 µm filter membrane; 60 µL of the
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filtrate was analyzed on SEC-HPLC. The stability profile was generated by plotting the
percentage of remaining CPT on the polymer over a time course. The percentage was
calculated based on the peak area of UV absorbance at 370 nm. The sample was also
analyzed on RP-HPLC and the integrity (lactone vs carboxylate) of the released CPT was
based on the retention times.


Cell culture of polyMPC-g-CPT conjugates

The COLO 205 and OVCAR 3 cancer cells were cultured in RPMI-1640 medium
supplemented with 10 % fetal bovine serum (FBS) or 20 % FBS and 0.01 mg/ml bovine
insulin, while MCF7 cells were cultured in MEM medium supplemented with 10 % FBS
and 0.01 mg/ml bovine insulin. All cells were grown in 5 % CO2 incubators at 37 ˚C.
For in vitro cytotoxicity assays cells were seeded into 96 well plates and after reaching
about 40 % cell density were incubated for 72-96 hours with varying camptothecin
equivalent concentrations of polymer drug conjugates as well as polymer control (i.e.,
without drug attachment). Cell viability post-treatment was measured using CellTiter-Glo
luminescent cell viability assays (Promega) as per manufacturer’s instructions on a
FLUOstar OPTIMA plate reader (BMG LABTECH). The percentage camptothecin
mediated toxicity was calculated with respect to untreated cells, and graphed to give dose
response curves. IC50 values for each treatment were then calculated using the GraphPad
Prism4 statistical analysis software.


Determination of critical micelle concentration (CMC) for poly(MPC-b-

DHLA)
CMC was determined using a pyrene fluorescence probe. Briefly, a stock solution of
pyrene in acetone (1.2 x 10-4 M) was prepared. Polymers 55 A-C were dissolved in PBS,
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and diluted from 5 mg/ml to 1.25 μg/mL, with each solution having a total volume of 1
mL. 5 μL of pyrene solution was added to each for a final pyrene concentration of 6 x
10-7 M. The polymer solutions were kept at 18 °C for 18 hours. An excitation spectrum
was recorded of each solution from 300-360 nm at a scan rate of 100 nm/s, with emission
set to 394 nm. CMC was determined by plotting log(concentration) vs. the ratio of the
intensities at 339 and 334 nm.


CPT release from cross-linked polyMPC-b-DHLA micelles

Release of CPT from the polymer micelles was monitored by dialysis.

Briefly,

lyophilized polymer micelles containing CPT were dissolved in PBS (1 mL).

The

solution was transferred to a dialysis cassette (MWCO 3500) by syringe. The cassette
was suspended in a sealed container with 300 mL of PB, or PBS containing 3 mM DTT.
Containers were kept in a water bath at 37 °C, and at select time points 1 mL aliquots
were removed from the external media and replaced with fresh buffer. The fluorescence
intensity at 440 nm (λex=370 nm) was monitored, and the experiments were carried out
until a plateau was reached.


Cell culture of CPT-loaded polyMPC-b-DHLA micelles

COLO205 cancer cells were cultured in RPMI-1640 medium supplemented with 10%
fetal bovine serum (FBS), while MCF7 cells were cultured in MEM medium
supplemented with 10% FBS and 0.01 mg/mL bovine insulin. All cells were grown in 5
% CO2 incubators at 37 °C. For in vitro cytotoxicity assays, cells were seeded in 96 well
plates, and after reaching about 40 % cell density were incubated for 72 hours with
varying camptothecin equivalent concentrations of prodrug micelles, as well as control
samples, including polymer only and polymer micelles (physically entrapped CPT). Cell
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viability post-treatment was measured using CellTiter-Glo luminescence cell viability
assay (Promega) following the manufacturer instructions on a FLUOstar OPTIMA plate
reader (BMG LABTECH). The CPT-mediated toxicity was calculated with respect to
untreated cells, and graphed to give dose-response curves. IC50 values for each treatment
were then calculated using GraphPad Prism4 statistical analysis software.


Pharmacokinetics of polyMPC-DOX

All experiments were performed in accordance with protocols approved by the Baystate
Institutional Animal Care and Use Committee. Four week old BALB/c female mice were
injected subcutaneously into the right flank with 5 x 106 4T1 murine breast cancer cells
suspended in 100 µL of Hank’s Balanced Salt Solution (HBSS). Once tumors reached a
size of 100-300 mm3 (calculated by L x W2 x π/6), mice were injected through the lateral
tail vein with 100 µL HBSS, free doxorubicin (6 mg/kg), or polyMPC-DOX (6 mg/kg,
DOX equivalent) (n=8/treatment).

Blood samples (30-50 µL) were taken from the

submandibular vein prior to injection, and then 30 minutes, 2 hours, 6 hours, 12 hours, 1
day, 2 days, 3 days, and 5 days post-injection. Blood samples were clotted on ice and
centrifuged at 1500 x g for 15 minutes at 4 ˚C. Serum was collected and stored at -80 ˚C
until HPLC analysis to determine doxorubicin concentration. On day 3 and day 5 postinjection, mice were euthanized from each treatment group. For HPLC analysis, 10 μL of
each serum sample was diluted with 90 μL of HPLC mobile phase (40 % acetonitrile in
water + 1 % trifluoroacetic acid), and incubated at room temperature for 2 hours, then
overnight at 4 °C. Samples were centrifuged to sediment residual debris, and 25 μL was
injected on the HPLC fitted with a reverse phase (C18) column, and monitoring with
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fluorescence detection (480/580 nm, ex/em). DOX concentration was determined using a
calibration curve, then plotted against post-injection time to generate the PK profile.


Immunogenicity of polyMPC-DOX

Following completion of the PK study, blood from each mouse was collected by cardiac
puncture (800 μL), and a complete blood count (CBC) was performed on 500 µl using the
VetScan HM5. The remainder of the samples were allowed to clot on ice, centrifuged at
1500 x g for 15 minutes at 4 ˚C, serum was collected and stored at -80 ˚C for ELISA of
cytokine responses.


Biodistribution of polyMPC-DOX

Tumors, hearts, livers, lungs, kidneys, and spleens, were collected, weighed, and frozen
in liquid nitrogen. Livers and spleens were divided and half of each tissue was
additionally fixed in 10% buffered formalin overnight at 4 ˚C, transferred to 70 % EtOH
at 4 ˚C, and paraffin embedded for histological analysis. Frozen tissues were
homogenized at maximum speed in acidified isopropanol (90 % isopropanol containing
0.6 mL concentrated HCl). Samples were then centrifuged at 1500 x g for 15 minutes at 4
˚C, and the upper aqueous phase was collected and stored at -80 ˚C until HPLC analysis
of doxorubicin concentration. 50 μL of each tissue homogenate was transferred to a
clean vial, and the IPA was evaporated under a stream of nitrogen, and redissolved in 50
μL of HPLC mobile phase (40 % acetonitrile in water + 1 % trifluoroacetic acid).
Samples were centrifuged for 30 minutes at 12,000 rpm to sediment precipitated proteins
and cell debris. 25 μL was injected in the HPLC equipped with a reverse phase (C18
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column), monitoring with fluorescence detection. DOX concentration was calculated
using a calibration curve, then normalized per gram of tissue.


Antitumor efficacy of polyMPC-DOX in 4T1 tumor-bearing mice

Four week old BALB/c female mice were injected into lower right mammary fat pad with
5x106 4T1 murine breast cancer cells suspended in 100 µL of Hank’s Balanced Salt
Solution (HBSS). Once tumors reached a size of 42-132 mm3 (calculated by L x W2 x
π/6), mice were injected through the lateral tail vein with free doxorubicin (3mg/kg),
polyMPC-DOX (15mg/kg DOX equivalent), or HBSS (control) (n=15/treatment). A
second injection of the same concentration was given on Day 7, and mice treated with
polyMPC-DOX received a third dose on Day 17. Animals were monitored for signs of
distress, and body weights and tumor measurements were collected every 2 days. Upon
completion, tumors, hearts, livers, lungs, kidneys, and spleens, were collected, weighed,
and fixed in 10 % buffered formalin overnight at 4 ˚C, transferred to 70 % EtOH at 4 ˚C,
and paraffin embedded for histological analysis.


Cell culture, cell density, and proliferation studies for polyMPC hydrogels

Mouse skeletal muscle myoblasts C2C12 cells were cultured in growth medium
(Dulbecco’s Modified Eagles Medium, DMEM), while human ovarian adenocarcinoma
SKOV3 cells were cultured in growth medium (McCoy’s 5A) supplemented with 10 %
Fetal Bovine Serum (FBS) and Penicillin and Streptomycin, at 37 °C in a 5 % CO2
incubator. Gels were prepared in a tissue culture 24-well plate, according to the general
procedure described previously, with a final solution volume of 200 μL. The 24-well
plate was incubated at 37 °C for 20 minutes. The gels were rinsed and swollen in PBS
for 18 hours. The hydrogels were washed twice with sterile growth medium, and were

149

incubated with growth medium for 2 hours at 37 °C in 5 % CO2 incubator. The medium
was then replaced with 1 mL growth medium containing 10 × 104 proliferating C2C12 or
SKOV3 cells and incubated at 37 °C for up to 24 hours. Cell spreading and proliferation
were visualized by optical microscopy. Percent cell density was determined using the
CellTiter-Glo reagent and a luminescence plate reader.
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